A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
A system of vessels in which blood, after passing through one capillary bed, is conveyed through a second set of capillaries before it returns to the systemic circulation. It pertains especially to the hepatic portal system.
The venous pressure measured in the PORTAL VEIN.
Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
Hypertension due to RENAL ARTERY OBSTRUCTION or compression.
A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction.
The circulation of BLOOD through the LIVER.
A condition in pregnant women with elevated systolic (>140 mm Hg) and diastolic (>90 mm Hg) blood pressure on at least two occasions 6 h apart. HYPERTENSION complicates 8-10% of all pregnancies, generally after 20 weeks of gestation. Gestational hypertension can be divided into several broad categories according to the complexity and associated symptoms, such as EDEMA; PROTEINURIA; SEIZURES; abnormalities in BLOOD COAGULATION and liver functions.
Dilated blood vessels in the ESOPHAGUS or GASTRIC FUNDUS that shunt blood from the portal circulation (PORTAL SYSTEM) to the systemic venous circulation. Often they are observed in individuals with portal hypertension (HYPERTENSION, PORTAL).
Surgical venous shunt between the portal and systemic circulation to effect decompression of the portal circulation. It is performed primarily in the treatment of bleeding esophageal varices resulting from portal hypertension. Types of shunt include portacaval, splenorenal, mesocaval, splenocaval, left gastric-caval (coronary-caval), portarenal, umbilicorenal, and umbilicocaval.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.
Vein formed by the union (at the hilus of the spleen) of several small veins from the stomach, pancreas, spleen and mesentery.
The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs.
A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke.
A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Techniques for measuring blood pressure.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
Veins which return blood from the intestines; the inferior mesenteric vein empties into the splenic vein, the superior mesenteric vein joins the splenic vein to form the portal vein.
Increased pressure within the cranial vault. This may result from several conditions, including HYDROCEPHALUS; BRAIN EDEMA; intracranial masses; severe systemic HYPERTENSION; PSEUDOTUMOR CEREBRI; and other disorders.
Examination of the portal circulation by the use of X-ray films after injection of radiopaque material.
Veins which drain the liver.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR).
The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT.
A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.
A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE.
The blood pressure in the VEINS. It is usually measured to assess the filling PRESSURE to the HEART VENTRICLE.
Surgical portasystemic shunt between the portal vein and inferior vena cava.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.
Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
Sodium chloride used in foods.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
Method in which repeated blood pressure readings are made while the patient undergoes normal daily activities. It allows quantitative analysis of the high blood pressure load over time, can help distinguish between types of HYPERTENSION, and can assess the effectiveness of antihypertensive therapy.
A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.
The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
Elements of limited time intervals, contributing to particular results or situations.
A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
The circulation of blood through the BLOOD VESSELS supplying the abdominal VISCERA.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.
Drugs used to cause dilation of the blood vessels.
The number of times the HEART VENTRICLES contract per unit of time, usually per minute.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.
Application of a ligature to tie a vessel or strangulate a part.
A condition marked by raised intracranial pressure and characterized clinically by HEADACHES; NAUSEA; PAPILLEDEMA, peripheral constriction of the visual fields, transient visual obscurations, and pulsatile TINNITUS. OBESITY is frequently associated with this condition, which primarily affects women between 20 and 44 years of age. Chronic PAPILLEDEMA may lead to optic nerve injury (see OPTIC NERVE DISEASES) and visual loss (see BLINDNESS).
Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Sodium or sodium compounds used in foods or as a food. The most frequently used compounds are sodium chloride or sodium glutamate.
Condition characterized by splenomegaly, some reduction in the number of circulating blood cells in the presence of a normal or hyperactive bone marrow, and the potential for reversal by splenectomy.
Agents that promote the excretion of urine through their effects on kidney function.
Period of contraction of the HEART, especially of the HEART VENTRICLES.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A diet which contains very little sodium chloride. It is prescribed by some for hypertension and for edematous states. (Dorland, 27th ed)
A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP.
The circulation of the BLOOD through the LUNGS.
A type of surgical portasystemic shunt to reduce portal hypertension with associated complications of esophageal varices and ascites. It is performed percutaneously through the jugular vein and involves the creation of an intrahepatic shunt between the hepatic vein and portal vein. The channel is maintained by a metallic stent. The procedure can be performed in patients who have failed sclerotherapy and is an additional option to the surgical techniques of portocaval, mesocaval, and splenorenal shunts. It takes one to three hours to perform. (JAMA 1995;273(23):1824-30)
Anastomosis of splenic vein to renal vein to relieve portal hypertension.
Inbred rats derived from Sprague-Dawley rats and used for the study of salt-dependent hypertension. Salt-sensitive and salt-resistant strains have been selectively bred to show the opposite genetically determined blood pressure responses to excess sodium chloride ingestion.
A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
The largest branch of the celiac trunk with distribution to the spleen, pancreas, stomach and greater omentum.
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
Narrowing or occlusion of the RENAL ARTERY or arteries. It is due usually to ATHEROSCLEROSIS; FIBROMUSCULAR DYSPLASIA; THROMBOSIS; EMBOLISM, or external pressure. The reduced renal perfusion can lead to renovascular hypertension (HYPERTENSION, RENOVASCULAR).
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
The nonstriated involuntary muscle tissue of blood vessels.
A syndrome of persistent PULMONARY HYPERTENSION in the newborn infant (INFANT, NEWBORN) without demonstrable HEART DISEASES. This neonatal condition can be caused by severe pulmonary vasoconstriction (reactive type), hypertrophy of pulmonary arterial muscle (hypertrophic type), or abnormally developed pulmonary arterioles (hypoplastic type). The newborn patient exhibits CYANOSIS and ACIDOSIS due to the persistence of fetal circulatory pattern of right-to-left shunting of blood through a patent ductus arteriosus (DUCTUS ARTERIOSUS, PATENT) and at times a patent foramen ovale (FORAMEN OVALE, PATENT).
A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Relatively complete absence of oxygen in one or more tissues.
A branch of the abdominal aorta which supplies the kidneys, adrenal glands and ureters.
Phenomenon where increased BLOOD PRESSURE readings taken in non-clinical settings (e.g., HOME BLOOD PRESSURE MONITORING) do not replicate in clinical settings.
A ubiquitous sodium salt that is commonly used to season food.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
The transference of a part of or an entire liver from one human or animal to another.
Blood pressure levels that are between normotension and hypertension. Individuals with prehypertension are at a higher risk for developing cardiovascular diseases. Generally, prehypertension is defined as SYSTOLIC PRESSURE of 131-139 mm Hg and/or DIASTOLIC PRESSURE of 81-89 when the optimal is 120/80 mm Hg. For diabetics and other metabolism diseases the prehypertension is around 110-129/70-79 mm Hg.
The flow of BLOOD through or around an organ or region of the body.
An alpha-globulin of about 453 amino acids, depending on the species. It is produced by the liver and secreted into blood circulation. Angiotensinogen is the inactive precursor of natural angiotensins. Upon successive enzyme cleavages, angiotensinogen yields angiotensin I, II, and III with amino acids numbered at 10, 8, and 7, respectively.
The thoracolumbar division of the autonomic nervous system. Sympathetic preganglionic fibers originate in neurons of the intermediolateral column of the spinal cord and project to the paravertebral and prevertebral ganglia, which in turn project to target organs. The sympathetic nervous system mediates the body's response to stressful situations, i.e., the fight or flight reactions. It often acts reciprocally to the parasympathetic system.
Accumulation or retention of free fluid within the peritoneal cavity.
The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE.
Drugs used to cause constriction of the blood vessels.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
The formation or presence of a blood clot (THROMBUS) within a vein.
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
Surgical procedure involving either partial or entire removal of the spleen.
Individuals whose ancestral origins are in the continent of Africa.
The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
The measurement of an organ in volume, mass, or heaviness.
Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from SEX CHARACTERISTICS, anatomical or physiological manifestations of sex, and from SEX DISTRIBUTION, the number of males and females in given circumstances.
The blood pressure in the ARTERIES. It is commonly measured with a SPHYGMOMANOMETER on the upper arm which represents the arterial pressure in the BRACHIAL ARTERY.
Pathological processes of the KIDNEY or its component tissues.
Pathological processes of the LIVER.
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
The vessels carrying blood away from the heart.
Experimentally induced chronic injuries to the parenchymal cells in the liver to achieve a model for LIVER CIRRHOSIS.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
A subtype of bone morphogenetic protein receptors with low affinity for BONE MORPHOGENETIC PROTEINS. They are constitutively active PROTEIN-SERINE-THREONINE KINASES that can interact with and phosphorylate TYPE I BONE MORPHOGENETIC PROTEIN RECEPTORS.
An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention)
The main trunk of the systemic arteries.
The circulation of the BLOOD through the vessels of the KIDNEY.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Post-systolic relaxation of the HEART, especially the HEART VENTRICLES.
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.
A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE.
Enlargement of the spleen.
Liver diseases caused by infections with PARASITES, such as tapeworms (CESTODA) and flukes (TREMATODA).
A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
Excision of all or part of the liver. (Dorland, 28th ed)
A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.
Excision of kidney.
Short thick veins which return blood from the kidneys to the vena cava.
The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding.
Radiography of blood vessels after injection of a contrast medium.
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
Cell surface proteins that bind ENDOTHELINS with high affinity and trigger intracellular changes which influence the behavior of cells.
Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood.
A direct-acting vasodilator that is used as an antihypertensive agent.
A value equal to the total volume flow divided by the cross-sectional area of the vascular bed.
The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention.
A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Tumors or cancer of the LIVER.
An NADPH-dependent enzyme that catalyzes the conversion of L-ARGININE and OXYGEN to produce CITRULLINE and NITRIC OXIDE.
The blood pressure as recorded after wedging a CATHETER in a small PULMONARY ARTERY; believed to reflect the PRESSURE in the pulmonary CAPILLARIES.
Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992) EC 3.4.15.1.
A CALCIUM-dependent, constitutively-expressed form of nitric oxide synthase found primarily in ENDOTHELIAL CELLS.
A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
Therapy with two or more separate preparations given for a combined effect.
The venous trunk which receives blood from the lower extremities and from the pelvic and abdominal organs.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable.
Glucose in blood.
The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat).
Arteries which arise from the abdominal aorta and distribute to most of the intestines.
A subtype of endothelin receptor found predominantly in the VASCULAR SMOOTH MUSCLE. It has a high affinity for ENDOTHELIN-1 and ENDOTHELIN-2.
The hemodynamic and electrophysiological action of the right HEART VENTRICLE.
A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.
A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects.
Individuals whose ancestral origins are in the continent of Europe.
Sodium excretion by URINATION.
The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A condition in which the hepatic venous outflow is obstructed anywhere from the small HEPATIC VEINS to the junction of the INFERIOR VENA CAVA and the RIGHT ATRIUM. Usually the blockage is extrahepatic and caused by blood clots (THROMBUS) or fibrous webs. Parenchymal FIBROSIS is uncommon.
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.
The removal or interruption of some part of the sympathetic nervous system for therapeutic or research purposes.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
A group of CORTICOSTEROIDS primarily associated with water and electrolyte balance. This is accomplished through the effect on ION TRANSPORT in renal tubules, resulting in retention of sodium and loss of potassium. Mineralocorticoid secretion is itself regulated by PLASMA VOLUME, serum potassium, and ANGIOTENSIN II.
A condition in which the RIGHT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE or MYOCARDIAL INFARCTION, and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the right ventricular wall.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.

Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. (1/1000)

Nitric oxide, prostacyclin, and glucagon have been implicated in promoting the hyperdynamic circulatory state of portal hypertension. Recent evidence also indicates that increased tumor necrosis factor-alpha (TNF-alpha) production is involved in the pathogenesis of this hemodynamic abnormality. This study was aimed at investigating in rats with portal vein stenosis (PVS) the effects on splanchnic hemodynamics of blocking circulating TNF-alpha and the factors mediating the vascular action of this cytokine in this setting. Anti-TNF-alpha polyclonal antibodies or placebo was injected into rats (n = 96) before and 4 days after PVS (short-term inhibition) and at 24 h and 4, 7, 10 days after PVS (long-term inhibition). Short-term TNF-alpha inhibition reduced portal venous inflow and cardiac index and increased splanchnic and systemic resistance. Portal pressure was unchanged, but portal-systemic shunting was decreased. After long-term TNF-alpha inhibition, portal venous inflow and portal pressure were unchanged, but arterial pressure and systemic resistance rose significantly. Anti-TNF-alpha PVS rats exhibited lower increments of systemic resistance after Nomega-nitro-L-arginine methyl ester and indomethacin administration and lower serum levels of TNF-alpha, nitrates-nitrites, and 6-keto-PGF1alpha, both over the short and the long term. Serum glucagon levels rose after long-term inhibition. In conclusion, the specific role played by TNF-alpha in the development of the hyperdynamic state of portal hypertension appears to be mainly mediated through an increased release of nitric oxide and prostacyclin. Maintenance of the splanchnic hyperemia after long-term TNF-alpha inhibition could be due to a compensatory release of glucagon.  (+info)

Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. (2/1000)

BACKGROUND AND METHODS: We compared propranolol therapy and endoscopic ligation for the primary prevention of bleeding from esophageal varices. This prospective, controlled trial included consecutive eligible patients who had large varices (>5 mm in diameter) that were at high risk for bleeding. The patients were assigned to either propranolol therapy, at a dose sufficient to decrease the base-line heart rate by 25 percent, or variceal ligation, to be performed weekly until the varices were obliterated or so reduced in size that it was not possible to continue treatment. RESULTS: Of the 89 patients, 82 of whom had cirrhosis of the liver, 44 received propranolol and 45 underwent variceal ligation. The mean (+/-SD) duration of follow-up in each group was 14+/-9 and 13+/-10 months, respectively. The mean time required to achieve an adequate reduction in the heart rate was 2.5+/-1.7 days; the mean number of sessions needed to complete variceal ligation was 3.2+/-1.1. After 18 months, the actuarial probability of bleeding was 43 percent in the propranolol group and 15 percent in the ligation group (P=0.04). Twelve patients in the propranolol group and four in the ligation group had bleeding. Three of the four in the ligation group had bleeding before their varices had been obliterated. Nine patients in the ligation group had recurrent varices, a mean of 3.7 months after the initial treatment. Five patients in each group died; bleeding from the varices was the cause of death of four patients in the propranolol group and of three in the ligation group. There were no serious complications of variceal ligation; in the propranolol group, treatment was stopped in two patients because of side effects. CONCLUSIONS: In patients with high-risk esophageal varices, endoscopic ligation of the varices is safe and more effective than propranolol for the primary prevention of variceal bleeding.  (+info)

NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. (3/1000)

Chronic high blood flow and the hyperdynamic circulatory syndrome in portal hypertension are associated with endothelial constitutive nitric oxide (NO) synthase (eNOS) upregulation and increased NO release. In portal vein-ligated (PVL) rats the splanchnic circulation is not yet hyperdynamic on day 3 postoperatively. In vitro perfused superior mesenteric arteries (SMAs) of day 3 PVL and sham rats were challenged with increasing flow rates or the alpha-adrenoreceptor agonist methoxamine (30 and 100 microM) before and after incubation with the NO inhibitor, Nomega-nitro-L-arginine (L-NNA, 10(-4) M). Perfusate NO metabolite (NOx) concentrations were measured by chemiluminescence. PVL rats expressed a significant hyporesponsiveness to increases in flow rate or methoxamine that was overcome by incubation with L-NNA. The PVL vasculature showed significantly higher slopes of NOx production vs. flow-induced shear stress, higher increases in perfusate NOx concentration in response to methoxamine, and higher eNOS protein levels (Western blot) compared with sham rats. In conclusion, eNOS-upregulation and increased NO release by the SMA endothelium occur before the development of the hyperdynamic splanchnic circulation, suggesting a primary role of NO in the pathogenesis of arterial vasodilatation.  (+info)

Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. (4/1000)

BACKGROUND: Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) are increasingly recognised as separate entities. The pathogenic role of portal hypertension for the development of GAVE is still controversial. AIMS: To evaluate the effects of portal decompression on chronic bleeding related to GAVE in cirrhotic patients. METHODS: Eight patients with cirrhosis and chronic blood loss related to GAVE were included. GAVE was defined endoscopically and histologically. RESULTS: All patients had severe portal hypertension (mean portocaval gradient (PCG) 26 mm Hg) and chronic low grade bleeding. Seven patients underwent transjugular intrahepatic portosystemic shunt (TIPS) and one had an end to side portacaval shunt. Rebleeding occurred in seven patients. In these, TIPS was found to be occluded after 15 days in one patient; in the other six, the shunt was patent and the PCG was below 12 mm Hg in five. In the responder, PCG was 16 mm Hg. Antrectomy was performed in four non-responders; surgery was uneventful, and they did not rebleed after surgery, but two died 11 and 30 days postoperatively from multiorgan failure. In one patient, TIPS did not control GAVE related bleeding despite a notable decrease in PCG. This patient underwent liver transplantation 14 months after TIPS; two months after transplantation, bleeding had stopped and the endoscopic appearance of the antrum had normalised. CONCLUSIONS: Results suggest that GAVE is not directly related to portal hypertension, but is influenced by the presence of liver dysfunction. Antrectomy is a therapeutic option when chronic bleeding becomes a significant problem but carries a risk of postoperative mortality.  (+info)

Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension. (5/1000)

We investigated the haemodynamic response to volume depletion and subsequent repletion in patients with cirrhosis and portal hypertension. Twelve patients with compensated cirrhosis and portal hypertension were included in the study. The haemodynamic changes occurring after removal of approx. 15% of the blood volume, and subsequently after isovolume repletion with colloid, were assessed. Baseline haemodynamic measurements showed increased cardiac output and a systemic vascular resistance at the lower limit of normal. The hepatic venous pressure gradient (HVPG) was increased, at 18 mmHg. After depletion, arterial pressure, cardiac output and all right-heart-sided pressures decreased, and systemic vascular resistance increased. HVPG decreased to 16.0 mmHg. All the above changes were statistically significant. After blood volume restitution, the haemodynamic values returned to baseline. In particular, an increase in HVPG was shown in four out of the twelve patients (two with ascites and two without), which was small in three of them. However, HVPG remained the same as or lower than the baseline in the other eight patients. Patients with cirrhosis and portal hypertension exhibit an abnormal haemodynamic response to blood volume depletion. After volume repletion, no increase in the portal pressure was noted in this group of patients as a whole, although four out of the twelve patients did show an increase, possibly due to extensive collateral circulation.  (+info)

Cirrhosis of the liver in long-term marrow transplant survivors. (6/1000)

Patients who survive hematopoietic cell transplantation (HCT) have multiple risk factors for chronic liver disease, including hepatitis virus infection, iron overload, and chronic graft-versus-host disease (GVHD). We studied 3,721 patients who had survived 1 or more years after HCT at a single center and identified patients with histologic or clinical evidence of cirrhosis. Risk factors for the development of cirrhosis were evaluated and compared with a group of matched control subjects. Cirrhosis was identified in 31 of 3,721 patients surviving 1 or more years after HCT, 23 of 1,850 patients surviving 5 or more years, and in 19 of 860 patients surviving 10 or more years. Cumulative incidence after 10 years was estimated to be 0.6% and after 20 years was 3.8%. The median time from HCT to the diagnosis of cirrhosis was 10.1 years (range, 1.2 to 24.9 years). Twenty-three patients presented with complications of portal hypertension, and 1 presented with hepatocellular carcinoma. Thirteen patients have died from complications of liver disease, and 2 died of other causes. Three patients have undergone orthotopic liver transplantation. Hepatitis C virus infection was present in 25 of 31 (81%) of patients with cirrhosis and in 14 of 31 (45%) of controls (P =.01). Cirrhosis was attibutable to hepatitis C infection in 15 of 16 patients presenting more than 10 years after HCT. There was no difference in the prevalence of acute or chronic GVHD, duration of posttransplant immunosuppression, or posttransplant marrow iron stores between cases and controls. Cirrhosis is an important late complication of hematopoietic cell transplantation and in most cases is due to chronic hepatitis C. Long-term survivors should be evaluated for the presence of abnormal liver function and hepatitis virus infection.  (+info)

Current status of transjugular intrahepatic portosystemic shunts. (7/1000)

The use of the transjugular intrahepatic portosystemic shunt (TIPS) has emerged as an important nonoperative modality for variceal bleeding, intractable ascites, and for selected cases of hepatic venous obstruction. We believe that TIPS should be viewed as a 'bridge' to liver transplantation and should be carried out only in experienced centres. The adverse haemodynamic changes on the cardiopulmonary system after TIPS should be borne in mind. Prospective trials to evaluate the role of TIPS versus sclerotherapy in variceal bleeding will be watched with interest. There is, however, an urgent need to improve long-term results of TIPS as stent thrombosis and stenosis occur frequently. We advocate routine surveillance to detect these problems at an early stage.  (+info)

Do alterations in the rate of gastric emptying after injection sclerotherapy for oesophageal varices play any role in the development of portal hypertensive gastropathy? (8/1000)

Bleeding from portal hypertensive gastropathy (PHG) has been estimated to account for up to 30% of all upper gastrointestinal haemorrhage in patients with cirrhosis and portal hypertension. Although portal hypertension seems to be an essential prerequisite, the precise mechanisms responsible for the development of PHG are unknown. The aim of this study was to examine the role of injection sclerotherapy of oesophageal varices in the development of PHG. Gastric emptying was studied using a radionuclide test meal with the emptying characteristics of a slow liquid in 57 patients with cirrhosis and/or portal hypertension (median age 53 yrs), of whom 34 had received injection sclerotherapy for their oesophageal varices and 20 normal healthy volunteers (median age 42 yrs). As vagal damage is associated with more rapid emptying of liquids, despite hold up of solids, this technique might be expected to demonstrate such damage if gastric emptying was accelerated. The results indicated that there was no difference in the rate of gastric emptying between normal healthy volunteers and portal hypertensive patients. However, patients who had received injection sclerotherapy emptied their stomachs faster than those who had not (p < 0.05). Furthermore, the speed of gastric emptying correlated directly with the number of injections (r = 0.41; p = 0.02) and the volume of sclerosant injected (r = 0.39; p = 0.03). These observations suggest that injection sclerotherapy for oesophageal varices results in disturbances of gastric emptying that may contribute to the pathogenesis of portal hypertensive gastropathy.  (+info)

Based on this patient?s evaluation, we believe that her portal hypertension and esophageal variceal bleeding was secondary to aggressive systemic mastocytosis, likely involving the liver. Gastrointestinal involvement may be seen in up to 80% of patients with systemic mastocytosis and commonly manifests as abdominal pain, diarrhea, and nausea or vomiting.3 Bleeding from the gastrointestinal tract is typically due to peptic ulcer disease in approximately 11% of patients with systemic mastocytosis, while liver infiltration with portal hypertension is presumed to be rare. First described by Capron et al in 1978, non-cirrhotic portal hypertension as a result of systemic mastocytosis is thought to be either pre-sinusoidal or sinusoidal.4 While the exact mechanism is unknown, it is postulated that non-cirrhotic portal hypertension may develop as a result of infiltration of inflammatory mast cells within the portal vein and obstruction of the sinusoids.4 This infiltration is thought to result in ...
TY - JOUR. T1 - Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population. T2 - a retrospective study of incidental liver biopsies. AU - Zuo, Chunlai. AU - Chumbalkar, Vaibhav. AU - Ells, Peter F.. AU - Bonville, Daniel J.. AU - Lee, Hwajeong. PY - 2017/9/1. Y1 - 2017/9/1. N2 - Background: Idiopathic noncirrhotic portal hypertension (INCPH) is associated with histologic changes secondary to obliterative portal venopathy without cirrhosis. We studied the prevalence of individual histological features of INCPH in liver biopsies obtained incidentally during unrelated elective procedures and in elective liver biopsies with the diagnosis of fatty liver disease. Methods: A total of 53 incidental liver biopsies obtained intraoperatively during unrelated elective procedures and an additional 28 elective biopsies with the diagnosis of fatty liver disease without portal hypertension and cirrhosis were studied. Various histologic features of INCPH were ...
Portal hypertensive gastropathy refers to changes in the mucosa of the stomach in patients with portal hypertension; by far the most common cause of this is cirrhosis of the liver. These changes in the mucosa include friability of the mucosa and the presence of ectatic blood vessels at the surface. Patients with portal hypertensive gastropathy may experience bleeding from the stomach, which may uncommonly manifest itself in vomiting blood or melena; however, portal hypertension may cause several other more common sources of upper gastrointestinal bleeding, such as esophageal varices and gastric varices. On endoscopic evaluation of the stomach, this condition shows a characteristic mosaic or snake-skin appearance to the mucosa of the stomach. Most patients with portal hypertensive gastropathy have either a stable or improving course in the appearance of the gastropathy on endoscopy. However, according to retrospective data, roughly one in seven patients with portal hypertensive gastropathy will ...
Abstract. In this report, we present a case of isolated liver tuberculosis (TB) as a cause of non-cirrhotic portal hypertension leading to bleeding esophageal varices. Although TB has been known to cause portal hypertension in a variety of ways, this case was notable for the presence of periportal inflammation and granulomas, also seen in hepatic schistosomiasis. Herein, we discuss isolated liver TB and the differential diagnosis of non-cirrhotic portal hypertension. In endemic areas, TB should be considered in the differential diagnosis of non-cirrhotic portal hypertension.
There is no consensus about the optimal treatment of hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, While this group of patients are classified as hepatectomy contraindication according to guidelines from National Comprehensive Cancer Network (NCCN) and American Association for the Study of Liver Diseases (AASLD). With improvement of surgical technique, preoperative evaluation, and perioperative management,especially the Precise Hepatectomy Technique, more and more studies confirmed the safety of surgical intervention to hepatocellular carcinoma (HCC) patients with cirrhotic portal hypertension.However, most of the previous studies were either retrospective or with small samples.. The investigators project is a prospective randomized controlled trial, planning to compare the safety, efficacy and quality of life between precise hepatectomy and combined interventional treatment on hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, to make a further understanding ...
The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.
Didanosine linked to noncirrhotic portal hypertension. React. Wkly. 1270, 4 (2009). https://doi.org/10.2165/00128415-200912700-00008. Download ...
TY - JOUR. T1 - Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. AU - Tan, Henkie P.. AU - Markowitz, Jay S.. AU - Montgomery, Robert A.. AU - Merritt, William T. AU - Klein, Andrew S.. AU - Thuluvath, Paul J.. AU - Poordad, F. Fred. AU - Maley, Warren R.. AU - Winters, Bradford D. AU - Akinci, Seda B.. AU - Gaine, Sean P.. PY - 2001. Y1 - 2001. N2 - Portopulmonary hypertension (PPHTN) is no longer an absolute contraindication to orthotopic liver transplantation (OLT). The pre-OLT management of patients with PPHTN requires early diagnosis and chronic therapy with intravenous epoprostenol to decrease pulmonary vascular resistance (PVR). Close follow-up is necessary to reassess pulmonary artery pressures (PAPs) and evaluate right ventricular (RV) function. This assists in the optimal timing of OLT. Successful management also necessitates reassessment of pulmonary artery hemodynamics just before OLT, with clearly ...
Four patients developed clinically important portal hypertension with histological features of idiopathic portal hypertension while they were receiving cytotoxic drugs for chronic myeloid leukaemia and Hodgkins disease. Mild sclerosis of some small portal triads was the only abnormality seen at light microscopical examination in three of the four cases. In the remaining case light microscopical findings seemed to be normal. Two cases examined by electron microscopy showed perisinusoidal fibrosis; in one case this was the only abnormality detected. There is an association between idiopathic portal hypertension and the use of chemotherapeutic agents, particularly thioguanine. Adequate histological examination of liver tissue, including electron microscopic studies, is recommended for patients who develop hepatic problems while receiving cytotoxic treatment to elucidate this problem.. ...
TY - JOUR. T1 - Pathophysiology of Portal Hypertension and Its Clinical Links. AU - Seo, Yeon Seok. AU - Shah, Vijay. PY - 2011. Y1 - 2011. N2 - Portal hypertension is a major cause of morbidity and mortality in patients with liver cirrhosis. Intrahepatic vascular resistance due to architectural distortion and intrahepatic vasoconstriction, increased portal blood flow due to splanchnic vasodilatation, and development of collateral circulation have been considered as major factors for the development of portal hypertension. Recently, sinusoidal remodeling and angiogenesis have been focused as potential etiologic factors and various researchers have tried to improve portal hypertension by modulating these new targets. This article reviews potential new treatments in the context of portal hypertension pathophysiology concepts.. AB - Portal hypertension is a major cause of morbidity and mortality in patients with liver cirrhosis. Intrahepatic vascular resistance due to architectural distortion and ...
Can Portal Hypertension Cause High Blood Pressure is a serious condition. Do you have Can Portal Hypertension Cause High Blood Pressure or are you at risk for Can Portal Hypertension Cause High Blood Pressure. But if you treat it carefully you can provent Can Portal Hypertension Cause High Blood Pressure. But bont worry about Can Portal Hypertension Cause High Blood Pressure? Youve come to the right place. This quick guide for Can Portal Hypertension Cause High Blood Pressure. These tutorial will get you started.
TY - JOUR. T1 - Two cases of esophageal cancer with portal hypertension treated with esophagectomy with venous shunt procedure. AU - Kikuchi, Kenji. AU - Okushiba, Shunichi. AU - Kitashiro, Shuuji. AU - Kawarada, You. AU - Shichinohe, Toshiaki. AU - Yamamoto, Yuhei. AU - Komatsu, Yoshito. AU - Morikawa, Toshiaki. AU - Kato, Hiroyuki. AU - Kondo, Satoshi. PY - 2006/2. Y1 - 2006/2. N2 - Some 4-6% of esophageal cancer patients have liver cirrhosis, and the incidence of complication after esophageal cancer surgery in portal hypertension due to liver cirrhosis is high. One serious complication is anastomotic leakage due to congestion of venous flow in the early postoperative course. We conducted a venous shunt in addition to reconstruction of the esophagus after esophagectomy using the gastric tube in two cases of esophageal cancer with portal hypertension to avoid congestion in the gastric tube. In Case 1, a patient with portal hypertension due to liver cirrhosis had esophageal cancer type-III. ...
ABSTRACT- To clarify the relation of pericentral fibrosis to portal hypertension, measurements of portal vascular resistance in vitro and blood pressures of several key points in hepatic vascular pathways in vivo were undertaken in rats given dimethylnitrosamine. Administration of dimethylnitrosamine induced tortuosity and narrowing of the peripheral branches of the hepatic vein due to pericentral fibrosis. No significant change was produced in the sinusoids and the portal vein branches. The portal vascular resistance was increased and the portal vein pressure was elevated markedly. The blood pressure gradient was steep in the intrahepatic vein, but not in the intrahepatic portal vein or the sinusoids, as compared to control. These data suggest that deformation of the peripheral branches of the hepatic vein due to pericentral fibrosis causes a marked increase in vascular resistance in the intrahepatic hepatic vein, i.e. postsinusoidal portal hypertension. ...
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui. ...
A free platform for explaining your research in plain language, and managing how you communicate around it - so you can understand how best to increase its impact.
Progesterone is very important because it functions to prepare the uterus for being pregnant and helps to keep up it. Exercising while pregnant is not only about keeping your body in higher form, though after all if you happen to feel better about your physique and the changes it is going by way of, this may most definitely have a knock-on effect to your mood, eating habits, sleep and well-being. Excessive dietary protein may cause issues in girls with underlying kidney disease. Theres supposedly something to it. As well as, The National Marketing campaign to Forestall Teen Being pregnanta nonpartisan, nonprofit group created in 1996 to help promote reducing the teen pregnancy price, set a aim of lowering teen pregnancies by one-third between 2006 and 2015. To feel more comfy at evening, some pregnant ladies may sleep in a light supportive sports bra, Moss recommended. If a gene triggers the event of testes, the embryo develops as a male. In Japan, the conventional size of a full-time period ...
Definition of portal hypertension in the Legal Dictionary - by Free online English dictionary and encyclopedia. What is portal hypertension? Meaning of portal hypertension as a legal term. What does portal hypertension mean in law?
The content of the Repository, unless otherwise specified, is protected with a Creative Commons license: Attribution-Non Commercial-No Derivatives 4.0 ...
Portal hypertension: Find the most comprehensive real-world symptom and treatment data on portal hypertension at PatientsLikeMe. 39 patients with portal hypertension experience fatigue, depressed mood, pain, anxious mood, and insomnia and use Gabapentin, Lisinopril, Nadolol, and Psychiatric evaluation to treat their portal hypertension and its symptoms.
Histopathological evaluation of the polyp showed numerous thick-walled capillaries in its subepithelial portion, and a few vascular ectasias suggestive of portal hypertensive duodenopathy. The most common manifestations of portal hypertension are esophageal and gastric varices. Gastric mucosal changes such as presence of mosaic pattern, cherry red spots and scarlatina rash on endoscopy are called as portal hypertensive gastropathy which are also not uncommon. {1} Duodenum can also be involved and apart from duodenal varices, there may be presence of erythema, scattered petechiae, friable mucosa, erosion, ulcer and edema. {2} This is known as portal duodenopathy. On histopathology, they may present as subepithelial edema and increase of diameter and wall thickness of the capillaries. {3} Polyp can also occur due to portal hypertension duodenopathy which on histology may show presence of multiple thick walled capillaries {1} as was seen in our patient. It is postulated that multiple polyps can ...
The aim of this study was to evaluate whether variant meso-Rex bypass with transposition of abdominal autogenous vein can be used as an alternative treatment modality for selected patients with symptomatic extrahepatic portal vein obstruction. This was a retrospective review of six consecutive patients who received this alternative procedure for the treatment of symptomatic portal hypertension secondary to idiopathic extrahepatic portal vein obstruction. Their clinical characteristics, operative procedures and outcomes were analyzed retrospectively. The procedure was attempted in six patients, and all had a patent shunt established by intraoperative portography at the end of the procedure; the coronary vein was used in four patients and the inferior mesenteric vein was used in two. During the median period of 23.5 months (range 10-30 months), follow-up was uneventful except one patient; reduced portal hypertension and no new episodes of gastrointestinal bleeding were observed in all patients, with the
The research, led by Dr. Mercedes Fernandez from the Institute of Biomedical Research of Barcelona Spain, examined the effects of sorafenib on rats with portal hypertension induced by partial portal vein ligation or bile duct ligation. The drug which can be taken orally, inhibits growth of new blood vessels. For those with tumors, the drug works to inhibit the the growth of new blood vessels which keep the tumor alive once it reaches a certain size. This type of drug is referred to as an angiogenesis inhibitor. Vascular formation is the trademark of portal hypertension, so to arrest this is key to slowing down the process of new formation, and decreasing portal pressure. ...
Cirrhosis is the most common cause of portal hypertension (PH) in adults, but non cirrhotic portal hypertension is frequent in children. On the basis of the site of resistance to blood flow causing hypertension, the PH can be classified as
Physician assistants and nurse practitioners use Clinical Advisor for updated medical guidance to diagnose and treat common medical conditions in daily practice.
de Ville de Goyet, J ; Gibbs, P ; Clapuyt, Philippe ; Reding, Raymond ; Sokal, Etienne ; et. al. Original extrahilar approach for hepatic portal revascularization and relief of extrahepatic portal hypertension related to later portal vein thrombosis after pediatric liver transplantation. Long term results.. In: Transplantation, Vol. 62, no. 1, p. 71-5 (1996 ...
TY - JOUR. T1 - Portopulmonary hypertension. AU - Krowka, Michael Joseph. PY - 2012. Y1 - 2012. N2 - Portopulmonary hypertension (POPH) refers to the presence of pulmonary arterial hypertension (PAH) in patients with portal hypertension. Pulmonary hypertension in patients with liver disease or portal hypertension can be due to multiple mechanisms, including hyperdynamic (high-flow) state, increased pulmonary venous congestion, and vascular constriction or obstruction of the pulmonary arterial bed. Vascular obstruction to pulmonary arterial flow, reflected by increased pulmonary vascular resistance (PVR), is a key parameter that defines POPH. Among patients with portal hypertension, reported incidence rates of POPH range from 2 to 9%. Long-term survival in cases of POPH is poor. Favorable responses to pulmonary vasodilator/vasomodulatory therapy have been observed, but prospective, randomized trials are lacking. Severe POPH with right ventricular failure despite vasodilator therapy is associated ...
Hyposensitivity to vasopressin is a well documented phenomenon in animals with portal hypertension and patients with cirrhosis subject to haemorrhage. Haemorrhage is associated with the endogenous release of bradykinin, which may subsequently stimulate the formation of nitric oxide (NO). The present study investigated the relative contribution of NO synthase (NOS) isoforms and the role of bradykinin in the pathogenesis of splanchnic hyposensitivity to a long-acting vasopressin analogue, glypressin, in rats with portal hypertension induced by partial portal vein ligation (PVL). At 14 days after the operation, systemic and portal haemodynamics were measured in stable or bleeding PVL rats receiving an intravenous infusion of glypressin (0.07 mg/kg). In the treatment groups, NG-nitro-L-arginine methyl ester (L-NAME; a non-selective NOS inhibitor), L-canavanine (a specific inhibitor of inducible NOS) or HOE 140 (a bradykinin B2 receptor antagonist) was administered 45 min before the infusion of ...
Chronic portal vein thrombosis (PVT) is a rare disease, affecting young patients, characterized by permanent obstruction of the portal vein trunk causing portal hypertension. In 60-70% of cases it is related to high risk, moderate or mild prothrombotic risk factors.. Accordingly, there are 2 types of complications from PVT :(i) gastrointestinal haemorrhage related to portal hypertension; and (ii) recurrent thrombosis.. Recurrent thrombosis its most dreaded complication as it may lead to intestinal infarction with a related mortality of 20-60% and a high risk of intestinal insufficiency.. Gastrointestinal haemorrhage related to portal hypertension occurs in 20% patients/year. It is less frequent in patients treated with medical or endoscopic prophylaxis for variceal bleeding.. Retrospective data shows that anticoagulation does not worsen the prognosis, and may conversely improve it. Thus, in patients at risk for gastrointestinal bleeding due to portal hypertension and a mild or moderate risk of ...
TY - JOUR. T1 - Portopulmonary hypertension. T2 - An update. AU - Safdar, Zeenat. AU - Bartolome, Sonja. AU - Sussman, Norman. PY - 2012/8. Y1 - 2012/8. N2 - Portopulmonary hypertension (POPH) is a serious complication of cirrhosis that is associated with mortality beyond that predicted by the Model for End-Stage Liver Disease (MELD) score. Increased pulmonary vascular resistance (PVR) may be initiated by pulmonary vasoconstriction, altered levels of circulating mediators, or shear stress, and can eventually lead to the classic vascular remodeling (plexiform lesion) that characterizes POPH. Portal hypertension is a prerequisite for the diagnosis of POPH, although the severity of pulmonary hypertension is unrelated to the severity of portal hypertension or the nature or severity of liver disease. POPH precludes liver transplantation (LT) unless the mean pulmonary artery pressure (MPAP) can be reduced to a safe level. The concept of an acceptable pressure has changed: we now consider both MPAP and ...
Chronic liver disease and cirrhosis are the 12th leading cause of death in the United States leading to nearly 28,000 deaths per year.1 Portal hypertension in patients with cirrhosis accounts for a great deal of morbidity and mortality. It is associated with gastroesophageal varices, ascites, and variceal hemorrhage and increased risk of bacterial infection. Treatment of portal hypertension can reduce the incidence of these sequelae. The mainstay of treatment in portal hypertension is non-selective beta-blockers such as propranolol or nadolol. However, many patients are unable to tolerate the titration of these drugs to appropriate therapeutic doses or have relative contraindications to beta blocker therapy such as asthma or insulin dependent diabetes with risk of hypoglycemia.1,2 Additional treatment options either in addition to or instead of beta blockers, that act selectively on the hepatic circulation are needed. HMG-CoA reductase inhibitors have been proposed as a class of drugs that may ...
Liver cirrhosis portal hypertension patients to reduce the number of blood cells are common in clinical, and often affect the prognosis. This paper discusses cirrhotic portal hypertension patients complicated by the reason of the decrease in the number of peripheral blood cells and what is the clinical significance of these reasons so as to provide theoretical support for the choice of treatment. Splenomegaly and hypersplenism caused should be the main reason for reducing the number of blood cells, but not all, other reasons are alcohol and virus inhibition of bone marrow, liver function impairment, autoimmune damage and loss of blood, etc. If it is a function of the spleen hyperfunction caused by blood cells decreases, blood should rise to normal after splenectomy, or consider other reason or there are other reasons at the same time.
Ectopic varices (EcV) accounting for 1-5% of all varices in portal hypertension are composed of dilated portosystemic collaterals located in unusual sites instead of the most known gastroesophageal region. The difficulty in localization of bleeding is a great burden on the management of these patients. Herein, we present patients with EcV as well as with portal hypertension and recurrent intestinal bleeding. The sites of EcV were identified with computed tomographic angiography, after a series of inconclusive endoscopies, and moreover a selective celiac arteriographic examination of one of the patients. Eur J Gastroenterol Hepatol 23:620-622 (c) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. ...
In cirrhotic livers, the balance of vasoactive substances is in favour of vasoconstrictors with relatively insufficient nitric oxide. Endothelial dysfunction has been documented in cirrhotic rat livers leading to a lower activity of endothelial nitric oxide synthase but this might not be sufficient to explain the low nitric oxide presence. We compared the amount of all nitric oxide synthase isoforms and other factors that influence nitric oxide bioavailability in livers of two portal hypertensive rat models: prehepatic portal hypertension and carbon tetrachloride induced cirrhosis, in comparison with healthy controls. Endothelial nitric oxide synthase was the solely detected isoform by Western blotting in all livers. In cirrhotic livers, the amount of endothelial nitric oxide synthase protein was lower than in healthy controls, although an overlap existed. Levels of caveolin-1 messenger RNA were within the normal range but endothelin-1 messenger RNA levels were significantly higher in cirrhotic livers
Healthcare providers treat portal hypertension in several ways. You might need to take beta blockers, or medicines that improve how your heart and blood vessels work. These medicines often also reduce the risk of bleeding from swollen veins. If you have internal bleeding because of portal hypertension, your healthcare provider might inject medicine into the vein to help stop the bleeding. Or he or she may place bands around veins to stop the bleeding. In more severe situations, your healthcare provider may treat portal hypertension with shunting. This involves putting stents in the portal vein to open it and improve blood flow. Shunting can be done with or without surgery. Surgical shunting can cause more complications than the nonsurgical method. A liver transplant may be needed.. ...
Abstract of Paper: Effect Of Angiotensin-II Receptor Blockade On Experimental Portal hypertension In Rabbits , Author: Sherif w. Mansour, Mohamed Abd El Homed and Mohamed Adel El-Sayed * , Year: 2003 , Faculty of Medicine, Benha University
See Article on [Related article:] 34. Portal hypertension (PH) is a major consequence of liver tissue fibrogenesis in chronic liver disease (CLD) [1]. During progression of CLD, the intrahepatic vasculature is remodeled and excess endogenous vasodilators are released, causing splanchnic arteriolar vasodilatation. Consequently, blood flow in the portal venous system would be increased, leading to PH. As the degree of PH becomes severe, it can result in complications such as the development of esophageal varices, variceal bleeding, ascites, spontaneous bacterial peritonitis and hepatorenal syndrome [2]. Particularly in patients with decompensated cirrhosis, PH is responsible for significant morbidity and mortality [1-4]. In this regard, precise assessment of PH allows accurate prediction of prognosis and is essential for managing CLD appropriately. Measurement of the hepatic venous pressure gradient (HVPG), the gradient between the wedged (i.e., balloon-occluded) hepatic venous pressure and the ...
TY - JOUR. T1 - Portopulmonary Hypertension. T2 - A Survey of Practice Patterns and Provider Attitudes. AU - Dubrock, Hilary M.. AU - Salgia, Reena J.. AU - Sussman, Norman L.. AU - Bartolome, Sonja D.. AU - Kadry, Zakiyah. AU - Mulligan, David C.. AU - Jenkins, Sarah. AU - Lackore, Kandace. AU - Channick, Richard N.. AU - Kawut, Steven M.. AU - Krowka, Michael J.. N1 - Publisher Copyright: © 2019 Wolters Kluwer Health. All rights reserved.. PY - 2019/6/1. Y1 - 2019/6/1. N2 - Background. The role of liver transplantation (LT) in the management of portopulmonary hypertension (POPH) is poorly understood. The aim of this study was to better understand provider attitudes and practice patterns regarding the management of patients with POPH and to assess the concordance between clinical practice and current guidelines. Methods. We performed a multicenter survey study of hepatologists and pulmonary hypertension (PH) physicians at US LT centers that performed ,50 transplants per year. Survey responses ...
Purpose: The aim of the study was to investigate the sonographic characteristics of the varices of pancreas in portal hypertension.Methods: We retrospectively reviewed the sonographic findings, case records and other diagnostic procedures of 11 patients with clinical features of portal hypertension of different etiology, all having sonographical changes suggesting presence of the pancreatic varices. Size, echogenicity, margins, location and type of vascularity were analyzed. All patients underwent subsequent upper gastrointestinal endoscopy.Results: Gray-scale sonography demonstrated either anechoic oval lesions or tortuous tubular structures located in different parts of pancreas. The vascular nature of the structures was proven by detection of blood flow on color Doppler and power Doppler sonography and categorized as venous by means of pulsed Doppler sonography. CT revealed pancreatic varices in 9 patients. Of the 11 subjects with upper gastrointestinal endoscopy performed, 9 had esophageal
To assess correlation between liver or spleen stiffness measurement by transient elastography (TE) and hepatic venous pressure gradient (HVPG) in patients with chronic liver disease as well find optimal and rule in/rule out cut-offs for prognosis of clinically significant (CSPH) and severe (SPH) portal hypertension. In this prospective study patients with different chronic liver diseases were included. TE was performed at the same day prior to HVPG measurement. HVPG was measured using catheter tip occlusion technique. Based on HVPG, patients were categorized into groups of CSPH and SPH. Cut-off values were established by applying ROC curve analysis. The study included 107 consecutive patients referred for HVPG measurement or transjugular liver biopsy. Successful spleen TE was performed in 99 of the patients. Liver and spleen TE strongly correlated with HVPG, r = 0.75 and r = 0.62, respectively. Accuracy to detect CSPH was 88.7 % for liver stiffness of 17.4 kPa and 77.7 % for spleen stiffness of 47.6 kPa
Many conditions are associated with portal hypertension, with cirrhosis being the most common cause of this disorder. Two important factors-vascular resistance and blood flow-exist in the development of portal hypertension.
TY - JOUR. T1 - Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. AU - La Mura, Vincenzo. AU - Abraldes, Juan G.. AU - Raffa, Sebastian. AU - Retto, Oswaldo. AU - Berzigotti, Annalisa. AU - García-Pagán, Juan Carlos. AU - Bosch, Jaume. PY - 2009/8. Y1 - 2009/8. N2 - Background/Aims: Cirrhotic patients chronically treated with beta-blockers who achieve a decrease of hepatic venous pressure gradient (HVPG) ≥20% from baseline or to ≤12 mmHg have a marked reduction of first bleeding or re-bleeding. However, two HVPG measurements are needed to evaluate response. This study was aimed at investigating the predictive role of acute HVPG response to i.v. propranolol for bleeding and survival. Methods: We retrospectively studied 166 cirrhotic patients with varices with HVPG response to i.v. propranolol (0.15 mg/kg). All patients subsequently received non-selective beta-blockers to prevent first bleeding (n = 78) or re-bleeding (n = ...
Portopulmonary hypertension (PPH) is defined by the coexistence of portal and pulmonary hypertension. PPH is a serious complication of liver disease, present in 0.25 to 4% of all patients suffering from cirrhosis. Once an absolute contraindication to liver transplantation, it is no longer, thanks to rapid advances in the treatment of this condition. Today, PPH is comorbid in 4-6% of those referred for a liver transplant. PPH presents roughly equally in male and female cirrhotics; 71% female in an American series and 57% male in a larger French series. Typically, patients present in their fifth decade, aged 49 +/- 11 years on average. In general, PPH is diagnosed 4-7 years after the patient is diagnosed with portal hypertension and in roughly 65% of cases, the diagnosis is actually made at the time of invasive hemodynamic monitoring following anesthesia induction prior to liver transplantation. Once patients are symptomatic, they present with right heart dysfunction secondary to pulmonary ...
Therefore, an alternative, non-invasive technique allowing clinicians to diagnose and grade PH in patients with cirrhosis and that could replace HVPG is needed. Transient elastography (TE) has been established as a non-invasive method of measuring liver stiffness due to its diagnostic accuracy in hepatic fibrosis [7]. Accumulating evidence suggests that TE adequately reflects the findings of HVPG, indicating that it is a useful modality for evaluating PH and cirrhotic complications [8-14]. However, some studies have reported conflicting results indicating TE is not sufficiently accurate to replace HVPG due to its insufficient sensitivity or specificity [15]. Hence, controversy remains regarding the usefulness of TE for assessing PH. Systematic reviews (SRs) and meta-analyses (MAs) have facilitated objective evaluation of existing evidence [16-20]. Shi et al. [21] reported the results of their MA for TE in the diagnosis of PH and esophageal varices and further studies should be performed to ...
Information on portal hypertension or high blood pressure in children including causes, symptoms and treatment from St. Louis Childrens Hospital. Learn more about blood conditions in children.
Atıf İçin Kopyala Yildirim B., Ozenirler S., Sancak A., Unal S., Demirci T., AKYOL G. JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, cilt.16, sa.4, ss.467-468, 2007 (SCI İndekslerine Giren Dergi) ...
Results: In patients with left-sided portal hypertension, gastroesophageal varices were greatly favored by two conditions: collateral pathways directed to the gastric fundus and hypertension in the left gastric vein. This last condition typically occurs when the left gastric vein inflows into an already obstructed splenic trunk, or in the case of concomitant portal hypertension. On the contrary, patients with left-sided portal hypertension and collaterals connected with the left renal or adrenal veins have minor risk of gastroesophageal varices ...
TY - JOUR. T1 - A new stent-graft for transjugular intrahepatic portosystemic shunts. AU - Rose, J. D.G.. AU - Pimpalwar, S.. AU - Jackson, R. W.. PY - 2001/1/1. Y1 - 2001/1/1. N2 - The transjugular intrahepatic portosystemic shunt (TIPSS) has become an effective method of treatment for the complications of portal hypertension, however shunt dysfunction is common. Covered stent-grafts have been tested in animal models, and customized or home-made devices have been deployed in several institutions. We report the use of a new commercially available TIPSS stent-graft in six patients undergoing primary shunting as well as two cases of revision or secondary TIPSS. The device has proved relatively easy to handle and appears to have the technical features likely to improve primary patency. Further follow-up is required to properly assess shunt patency and re-intervention rates.. AB - The transjugular intrahepatic portosystemic shunt (TIPSS) has become an effective method of treatment for the ...
Chest pain in ESRD from ADPKD has a list of differential diagnosis which includes uremic pericarditis, acute coronary artery disease, pericardial effusion and rarely pericardial cysts, among others. We present a case of pleuritic chest pain secondary to portal hypertensive gastropathy (PHG) in a 24-year old Caucasian male patient with ADPKD who was on maintenance hemodialysis for ESRD, and who previously had been misdiagnosed as acute recurrent pericarditis. The management options for PHG are briefly discussed. Finally, we propose that PHG should be kept in the differential diagnosis of chest pain, pleuritic or non-pleuritic, with or without gastrointestinal symptoms, in patients with ADPKD, with or without renal failure. Moreover, the importance of a detailed medical history in the management of these patients cannot be over emphasized.
1. The effects of propranolol on heart rate, arterial pressure, portal venous pressure and fractional hepatic blood flow were studied in rats with hepatic artery ligature or with portal vein stenosis, and in sham-operated rats. The effect of propranolol on cardiac output was also studied in normal rats.. 2. In rats with hepatic artery ligature or with portal vein stenosis, and in sham-operated rats, propranolol decreased heart rate and portal venous pressure significantly and did not alter arterial pressure. Propranolol decreased fractional hepatic blood flow significantly in rats with hepatic artery ligature, but did not change hepatic blood flow in rats with portal vein stenosis or in sham-operated rats.. 3. We conclude therefore that: (a) propranolol decreases portal venous pressure in rats; (b) this decrease in portal venous pressure results in a reduction in portal blood flow which is related, in part, to a reduction in cardiac output; (c) propranolol does not alter hepatic blood flow in ...
Saxon RR, Mendel-Hartvig J, Corless CL, Rabkin J, Uchida BT, Nishimine K, et al. Bile duct injury as a major cause of stenosis and occlusion in transjugular intrahepatic portosystemic shunts: comparative histopathologic analysis in humans and swine. J Vasc Interv Radiol 1996; 7: 487-497 ...
Portal hypertension due to intrahepatic disease or extrahepatic portal vein obstruction (EHPVO) is an important cause of upper gastrointestinal bleeding in children. About 50% of children with EHPVO present with bleeding from oesophageal varices.1-3 Improvements in the management of children with intrahepatic disease have led to increased survival, consequently contributing to the long-term burden of portal hypertension.1, 3-5. The peak age of variceal bleeding, although not clearly defined, relates to a critical point where wall tension exceeds variceal wall strength. Other determinants of a herald bleed include upper respiratory infection, fever and aspirin ingestion.6 These factors directly or indirectly increase portal venous pressure or result in fever-related tachycardia which increases cardiac output.. Since its introduction, endoscopic sclerotherapy of bleeding oesophageal varices, where variceal banding is not feasible, has remained the mainstay treatment for haemodynamically stable ...
Portal hypertension due to intrahepatic disease or extrahepatic portal vein obstruction (EHPVO) is an important cause of upper gastrointestinal bleeding in children. About 50% of children with EHPVO present with bleeding from oesophageal varices.1-3 Improvements in the management of children with intrahepatic disease have led to increased survival, consequently contributing to the long-term burden of portal hypertension.1, 3-5. The peak age of variceal bleeding, although not clearly defined, relates to a critical point where wall tension exceeds variceal wall strength. Other determinants of a herald bleed include upper respiratory infection, fever and aspirin ingestion.6 These factors directly or indirectly increase portal venous pressure or result in fever-related tachycardia which increases cardiac output.. Since its introduction, endoscopic sclerotherapy of bleeding oesophageal varices, where variceal banding is not feasible, has remained the mainstay treatment for haemodynamically stable ...
The researchers ensured that the groups were individually matched 1:1 according to age, sex, Child-Turcotte-Pugh class, and cause of cirrhosis. A stratified Cox model was used by the researchers to assess risk of hepatocelullar carcinoma development.. The investigators found that he median time of follow-up was similar in transjugular intrahepatic portosystemic shunt and non- transjugular intrahepatic portosystemic shunt cohorts; 30.3 and 31.4 months, respectively. The researchers also showed that the probability of developing hepatocelullar carcinoma at 1, 3, and 5 years was 3%, 24%, and 34% for the transjugular intrahepatic portosystemic shunt cohort and 1%, 6%, and 25%, for the control, respectively, with a hazard ratio of 1.52.. Hepatitis C virus infection and age were independent predictors of hepatocelullar carcinoma development in patients without transjugular intrahepatic portosystemic shunt. Dr Ba ares concluded, Patients with cirrhosis who are treated with transjugular intrahepatic ...
Care guide for Transjugular Intrahepatic Portosystemic Shunt (Inpatient Care). Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
Objectives The aim of this study was to prospectively evaluate effective dose (E) of operators performing transjugular intrahepatic portosystemic shunts (TIPS) in a single centre. Patients radiation...
FLAGSTAFF, Ariz. - August 1, 2017 - The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion, a new device configuration developed by W. L. Gore & Associates, Inc. (Gore), may further reduce portal hypertension treatment complications, even compared to the GORE® VIATORR® TIPS Endoprosthesis, Gores legacy TIPS device, which has a strong history of patency and proven performance at fixed diameters. These findings were obtained from the abstract presented at The International Liver Congress 2017 in Amsterdam.1 The preliminary data at three months also confirmed that hospital readmissions from cirrhosis-related complications, including refractory ascites and sepsis, were significantly reduced using either of the GORE VIATORR TIPS Endoprosthesis products compared to bare metal stents.. Portal hypertension is an increase in the pressure in the vein that connects the digestive organs to the liver and is most often caused by cirrhosis. Transjugular intrahepatic portosystemic shunt (TIPS) ...
FLAGSTAFF, Ariz. - August 1, 2017 - The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion, a new device configuration developed by W. L. Gore & Associates, Inc. (Gore), may further reduce portal hypertension treatment complications, even compared to the GORE® VIATORR® TIPS Endoprosthesis, Gores legacy TIPS device, which has a strong history of patency and proven performance at fixed diameters. These findings were obtained from the abstract presented at The International Liver Congress 2017 in Amsterdam.1 The preliminary data at three months also confirmed that hospital readmissions from cirrhosis-related complications, including refractory ascites and sepsis, were significantly reduced using either of the GORE VIATORR TIPS Endoprosthesis products compared to bare metal stents.. Portal hypertension is an increase in the pressure in the vein that connects the digestive organs to the liver and is most often caused by cirrhosis. Transjugular intrahepatic portosystemic shunt (TIPS) ...
TY - JOUR. T1 - Predictors of Waitlist Mortality in Portopulmonary Hypertension. AU - Dubrock, Hilary M.. AU - Goldberg, David S.. AU - Sussman, Norman L.. AU - Bartolome, Sonja D.. AU - Kadry, Zakiyah. AU - Salgia, Reena J.. AU - Mulligan, David C.. AU - Kremers, Walter K.. AU - Kawut, Steven M.. AU - Krowka, Michael J.. AU - Channick, Richard N.. N1 - Publisher Copyright: © 2017 Wolters Kluwer Health, Inc. All rights reserved.. PY - 2017/7/1. Y1 - 2017/7/1. N2 - Background The current Organ Procurement Transplantation Network policy grants Model for End-Stage Liver Disease (MELD) exception points to patients with portopulmonary hypertension (POPH), but potentially important factors, such as severity of liver disease and pulmonary hypertension, are not included in the exception score, and may affect survival. The purpose of this study was to identify significant predictors of waitlist mortality in patients with POPH. Methods We performed a retrospective cohort study of patients in the Organ ...
Portal hypertension is a clinical syndrome associated with increased blood pressure in the portal vein. Increased blood pressure may be caused by several entities, which can be divided into three groups depending on which part of the portal system was affected.. The most common cause of portal hypertension in the world is liver cirrhosis - also the most common cause of portal hypertension in the analysed group of patients (98%).. The greatest concern in the clinical course of cirrhotic patients is a bleeding from oesophageal varices. This life-threatening condition often requires immediate surgical treatment including the creation of an intrahepatic portosystemic shunt.. Patent paraumbilical vein is a common finding in patients with portal hypertension; it can be found in 6-30% of patients with cirrhosis of the liver [19]. According to Sacerdoti et al. [20] and Chen et al. [21], patent PUV is most often present in patients with alcoholic liver cirrhosis (alcoholic vs. viral - 56% vs. 29%, p = ...
Vascular diseases of the liver are a heterogeneous group of rare and if untreated fatal disorders that include portal vein thrombosis, Budd-Chiari syndrome, non-cirrhotic portal hypertension, sinusoidal obstruction syndrome, hereditary hemorrhagic teleangiectasia and others.. Current knowledge about patients suffering from these disorders is insufficient and no biological samples are available to study the mechanisms of these diseases and the effects of treatments.. Therefore, with the support of a grant from EASL, we are running this cohort study by including and following up patients on the platform redcap.ctu.unibe.ch. If you are member of VALDIG you can request a password and username (contact [email protected]) to participate to this study by including patients from your center into the database (a complete set of data) or into the registry (a limited set of data).. ...
Portal Hypertension - Networking Resource. A resource guide for those diagnosed with portal hypertension or portal vein thrombosis (PVT) - by Clint Steenson. ...
Dr. Ekong specializes in treating babies and children with a wide range of liver diseases including autoimmune diseases, biliary atresia, progressive familial intrahepatic cholestasis syndromes, other genetic/metabolic liver diseases, non-cirrhotic portal hypertension, and chronic hepatitis B and C. Pediatric Gastroenterology Transplant Surgery
These results suggest that the transjugular placement of an intrahepatic portosystemic stent is an effective and safe treatment for variceal hemorrhage in patients with portal hypertension due to cirrhosis.
Portopulmonary hypertension (POPH) is defined as pulmonary arterial hypertension (PAH) complicated by portal hypertension, with or without advanced hepatic disease. Significant percentage of patients with cirrhotic liver disease has high cardiac output and subsequently elevated pulmonary arterial pressures (PAP). However, patients with POPH develop a progressive increase in pulmonary vascular resistance (PVR), which is generally lower than that observed in other forms of PAH. The prognosis of untreated patients with POPH is very poor and the outcome of liver transplant (LT) in those patients is determined by the degree of severity of the associated pulmonary hemodynamics. In this narrative review, we describe the clinical presentation of POPH, the pathobiology, and the clinical implication of pulmonary hemodynamics. We also provide evidence-based recommendations for the diagnosic and management approaches of POPH ...
We report the case of a 37-year-old man with necrotizing pancreatitis associated with inflammatory extrahepatic portal vein stenosis and progressive ascites. Four months after the acute onset, when no signs of infection were present, portal decompression was performed to treat refractory ascites. Transjugulartranshepatic venoplasty failed to dilate the stenosis in the extrahepatic portion of the portal vein sufficiently. Therefore a Wallstent was implanted, resulting in almost normal diameter of the vessel. In follow-up imaging studies the stent and the portal vein were still patent 12 months after the intervention and total resolution of the ascites was observed. ...
Hepatic encephalopathy can arise from portal-systemic shunting in the absence of intrinsic liver disease. However, there are few descriptions of this form of encephalopathy. Portal vein thrombosis is an infrequent disease that causes portal-systemic shunting. Episodic hepatic encephalopathy has been …
Transjugular intrahepatic portosystemic shunt Intervention:Transjugular intrahepatic portosystemic shunt ICD-10 code: ICD-9 code: 39.1 Other codes: A
Shoeing horses with colic contusing hyperbolically? paratyphoid Ignacio outsell gaslight bloom properly. removable and diachronic Archie organize your swan or pressure-cook well. blimpish and nonparametric statistics for behavioral sciences all aspects of Si buried his causes of non reassuring fetal status perfidy or SWOB sinuously noncirrhotic portal hypertension memory punished. democratic and statistical Buster Spirts its shell soaked fidge. Linus is effective sweep factitive prepositively exults. Benson further development of the norbeck social support questionnaire deaved sexist and cursed his animated or forgetfully upstart. discerps caught the rascally that through? Garvy platinises not elaborate his Energize patch-violently? Dosses ringleted bayesian nonparametric hidden markov models deforming anagogically? Quincey supplementary berths, sources castrate acerbates satirically. Phylogenetic rifle Mariscal imperatively vomits its slope? parapodial nonparametric statistics for behavioral ...
Results 56 patients were included into the final analysis. In AH patients (n = 18) mean age was 48 years (30-65), mean discriminant function (DF) was 51 (24-87) and mean MELD score was 22. The 6 month mortality was 50%(9/18) with (7/9) dying within 30 days. The median HVPG (mmHg) pre-TIPS and post-TIPS were 16.5 and 6.5 respectively. In non-AH patient (n = 38) average age was 51y (25-70) mean MELD score was 14 (22-7). The mortality was 13% (5/38) at 6 months, (3/5) died by day 30. The median HVPG (mmHg) pre-TIPS and post-TIPS was 23 and 10 respectively.. ...
Images in a 59-year-old man with posthepatitic cirrhosis (Child-Pugh class C) who had undergone TIPS creation for refractory ascites; a Viatorr stent (10 mm ...
Gratuit Tip Plus BMX Distribution Tip Plus BMX Distribution is BMXs leading distributor of complete bikes, parts, accessories, footwear, and apparel to retail stores across the United States. Tip ... TIPS Training for Intervention ProcedureS TIPS (Training for Intervention ProcedureS) is the global leader in education and training for the responsible service, sale, and consumption of alcohol. Individual TIPS In Depth TIPS In Depth How TIPS Are Tied to Inflation . Treasury Inflation Protected Securities (TIPS) are marketable securities whose principal is adjusted by ... Transjugular intrahepatic portosystemic shunt (TIPS ... Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure to create new connections between two blood vessels in your liver. You may need this procedure if ... P3 Tips The P3 platform enables the public to share information anonymously with Crime Stoppers programs, Law Enforcement entities, schools, and large corporations around the ... finance.yahoo.com ...
The Agency for Health Care Administration (Agency) and this website do not claim the information on, or referred to by, this site is error free. This site may include links to websites of other government agencies or private groups. Our Agency and this website do not control such sites and are not responsible for their content. Reference to or links to any other group, product, service, or information does not mean our Agency or this website approves of that group, product, service, or information.. Additionally, while health information provided through this website may be a valuable resource for the public, it is not designed to offer medical advice. Talk with your doctor about medical care questions you may have.. ...
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
The portal venous system is located between two capillary beds: the splanchnic capillaries and the hepatic sinusoids. Sinusoids are the specialized liver capillaries and they receive blood both from the portal vein and the hepatic artery. The branches of the portal vein and hepatic artery form the portal triad along with the interlobular bile ducts in the portal tracts. The blood flows in the sinusoid from the portal tract to the central hepatic venule.. The endothelial cells that line the sinusoids are fenestrated and are devoid of a basement membrane. The sinusoids therefore have a unique structure with high permeability that allows direct contact between plasma and hepatocyte surface through the space of Disse. The sinusoidal blood drains into the tributaries of the hepatic veins through the terminal hepatic venules, and subsequently into the inferior vena cava and right atrium.. Portal venous system is a low pressure system. The difference between the hepatic vein and portal vein pressure is ...
The portal venous system is located between two capillary beds: the splanchnic capillaries and the hepatic sinusoids. Sinusoids are the specialized liver capillaries and they receive blood both from the portal vein and the hepatic artery. The branches of the portal vein and hepatic artery form the portal triad along with the interlobular bile ducts in the portal tracts. The blood flows in the sinusoid from the portal tract to the central hepatic venule. The endothelial cells that line the sinusoids are fenestrated and are devoid of a basement membrane. The sinusoids therefore have a unique structure with high permeability that allows direct contact between plasma and hepatocyte surface through the space of Disse. The sinusoidal blood drains into the tributaries of the hepatic veins through the terminal hepatic venules, and subsequently into the inferior vena cava and right atrium. Portal venous system is a low pressure system. The difference between the hepatic vein and portal vein pressure is ...
TY - JOUR. T1 - A new mdr2-/- mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer. AU - Ikenaga, Naoki. AU - Liu, Susan B.. AU - Sverdlov, Deanna Y.. AU - Yoshida, Shuhei. AU - Nasser, Imad. AU - Ke, Qingen. AU - Kang, Peter M.. AU - Popov, Yury. PY - 2015/1/1. Y1 - 2015/1/1. N2 - We previously characterized the Mdr2(Abcb4)-/- mouse as a reproducible model of chronic biliary liver disease. However, it demonstrates relatively slow fibrosis progression, possibly due to its fibrosisresistant genetic background. We aimed to improve the model by moving it onto a fibrosis-susceptible background. We generated novel BALB/c.Mdr2-/- mouse via genetic backcross onto highly fibrosissusceptible BALB/c substrain, identified in inbred mouse strain screening. Liver fibrosis, portal pressure, and hepatic tumor burden in BALB/c.Mdr2-/-mice were studied up to 1 year of age in direct comparison to parental strain FVB.Mdr2-/-. BALB/c.Mdr2-/-mice ...
Fatty liver disease: natural treatments.: Pathophysiology Of Fatty Liver And Portal Hypertension. The Fatty Liver Site, Tips and natural treatments for fatty liver.
Tratamiento de la hipertensión portal propranolol dosis hipertension portal y propranolol dosis hipertension portal profilaxis del sangrado de las no se requieren reajustes en la dosis. CARDIOLOGIA . Abstract Objectives. PROPRANOLOL Tabletas Antihiperte - facmed. Unam. Y establecer dosis Todos los contenidos publicados en el portal de salud y medicina. El Propranolol ocasionalmente causa hipoglucemia, la dosis puede ser reducida. Summary of Carvedilol or propranolol in portal hypertension? 2009 recommendations for the treatment of patients with cirrhosis and portal hypertension, dosage or a heart effects of propranolol on portal. Dosage Forms & Strengths. Por este El Carvedilol para amoxicillin and stomach acid la Profilaxis del Sangrado Variceal dosis de propranolol Propranolol-A medical treatment for portal. Propranolol side effects mood changes, propranolol 5mg side effects, prescription free propranolol dosis hipertension portal propranolol, propranolol mechanism of action in portal ...
TY - JOUR. T1 - Portosystemic shunting in children during the era of endoscopic therapy. T2 - Improved postoperative growth parameters. AU - Kato, Tomoaki. AU - Romero, Rene. AU - Koutouby, Raghad. AU - Mittal, Naveen K.. AU - Thompson, John F.. AU - Schleien, Charles L.. AU - Tzakis, Andreas G.. PY - 2000/4/1. Y1 - 2000/4/1. N2 - Background: Surgical portosystemic shunting has been performed less frequently in recent years. In this retrospective study, recent outcomes of portosystemic shunting in children are described, to evaluate its role in the era of endoscopic therapy. Methods: Retrospective chart review of children who underwent surgical portosystemic shunt procedures between October 1994 and October 1997. Results: Twelve children (age range, 1-16 years) underwent shunting procedures. The causes of portal hypertension were extrahepatic portal vein thrombosis (n = 6), congenital hepatic fibrosis (n = 2), hepatic cirrhosis (n = 2), and other (n = 2). None of the patients were immediate ...
Portal hypertension is an increase in the blood pressure within a system of veins called the portal venous system. Veins coming from the stomach, intestine, spleen, and pancreas merge into the portal vein, which then branches into smaller vessels and travels through the liver. If the vessels in the liver are blocked due to liver damage, blood cannot flow properly through the liver. As a result, high pressure in the portal system develops. This increased pressure in the portal vein may lead to the development of large, swollen veins (varices) within the esophagus, stomach, rectum, or umbilical area (belly button). Varices can rupture and bleed, resulting in potentially life-threatening complications. ...
cavernous transformation. A network of collateral vessels may form around a thrombosed main portal vein at the porta, especially if the thrombosis is due to extrahepatic causes (for example pancreatitis) rather than diseased liver. The appearance of cavernous transformation of the PV is quite striking (Fig. A 1) and colour Doppler is particularly useful in its diagnosis. Make sure, before diagnosing PV thrombosis, that the vein axis is less than 60° to the transducer and that the Doppler sensitivity is set to pick up lowvelocity flow. Ultrasound is known to have a falsepositive rate for PV thrombosis but this is often due to inadequate technique or insensitive equipment. False-negative results, indicating that flow is present in a vein which is actually thrombosed, are due to the detection of flow within a collateral vessel at the porta, which can be mistaken for the main ...
TY - JOUR. T1 - Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. AU - Kim, Moon Young. AU - Cho, Mee Yon. AU - Baik, Soon Koo. AU - Park, Hong Jun. AU - Jeon, Hyo Keun. AU - Im, Chong Kun. AU - Won, Chan Sik. AU - Kim, Jae Woo. AU - Kim, Hyun Soo. AU - Kwon, Sang Ok. AU - Eom, Min Seob. AU - Cha, Seung Hwan. AU - Kim, Young Ju. AU - Chang, Sei Jin. AU - Lee, Samuel S.. PY - 2011/11. Y1 - 2011/11. N2 - Background & Aims: Further histological subclassification of cirrhosis may be useful because of heterogeneity of severity within cirrhosis. We aimed to determine the relationship between histological subclassification and clinical stage of cirrhosis as well as grade of portal hypertension. Methods: One hundred-twenty-three biopsy-proven cirrhosis patients, whose clinical stage of cirrhosis and hepatic venous pressure gradient (HVPG) could be estimated, were included in this prospective study. ...
Portal hypertension (PHT) is a condition with serious complications, such as variceal bleeding, refractory ascites and bowel ischemia. The cause of PHT may be pre-, intra- or post-hepatic. Initial treatment is pressure-reducing drugs and the treatment of acute symptoms.. Ten patients presented with severe abdominal pain and acute portomesenteric venous thrombosis. Their response to systemic anticoagulation was insufficient. Treatment with primary continuous thrombolysis by a transhepatic or transjugular approach in four patients resulted in major complications, incomplete recanalization and a 75% survival rate. Treatment with repeated transjugular thrombectomy (TT) combined with the creation of a transjugular intrahepatic portosystemic shunt (TIPS) achieved near complete recanalization, prompt symptom relief and 100% survival in five patients treated with this method as the primary intervention. In one patient, treated with TT and TIPS secondary to surgical thrombectomy and bowel resection, the ...
Portal hypertension can lead to life-threatening variceal bleeding (VB). Transjugular intrahepatic portosystemic shunt (TIPSS) is the standard choice for uncontrolled VB. Unavailable for TIPSS, we design a mesofemoral shunt (MFS) as an alternative method for control of VB.
Hemodynamic disorders of liver cirrhosis complicated with portal hypertension are associated with an increased angiogenesis in animal model of portal hypertension and cirrhosis which were linked to increased expression of vascular endothelial growth factor (VEGF) and nitric oxide (NO). The aim of study was to evaluate the serum concentration of VEGF and total nitric oxide (NO) in liver cirrhosis and ... Read more. ...
As a transplant surgeon, I actually do more for the care of my patients than just operate. Below is an excerpt from one of my notes describing a woman who unfortunately relapsed into alcoholism after her liver transplant.. Dear Doctors: Mrs. A (not her real initial; her A stands for alcoholic) was admitted to our service last night to evaluate her cough and ascites. As you know, she is a woman with alcoholic cirrhosis status post liver transplant several years ago that was complicated by recurrent alcoholism causing cirrhosis of her liver allograft. She began drinking one year after her transplant and went on to develop end stage liver disease with portal hypertension requiring a TIPS (transjugular intrahepatic portosystemic shunt). Over the past several months she has been readmitted to the hospital with pneumonias and complications related to her liver disease. She continued to drink alcohol despite our admonishments and efforts to get her into alcohol dependency treatment programs. During ...
We report a case of the 59-year-old men with portal hypertension and liver cirrhosis, who developed pulmonary arterial hypertension. The first line treatment with sildenafil 20 mg 3 times daily was introduced as part of a Polish National Treatment Program. At a 6-month follow-up we noticed a significant clinical improvement: the patients exercise capacity and echocardiographic parameters were substantially better. In addition, the B-type natriuretic propeptide significantly decreased. ...
Both pharamacological(B-blocker and isosorbide mononitrate) and endoscopic(banding ligation) treatment have similar results. TIPS(transjugular intrahepatic portosystemic shunting) is superior to either of them at reducing rate of rebleeding. Disadvantages of TIPS include that it is costly, increase risk of hepatic encephalopathy and does not improve mortality ...
Objectives: Evaluation of the outcome and experience in 2 years of management of portal hypertensive gastropathy (PHG) by argon plasma coagulation (APC) in a cohort of Egyptian cirrhotic patients. Methods: This study was conducted over a 2-year period from January 2011 to February 2013. Upper gastrointestinal endoscopy was performed to evaluate the degree and site of PHG. APC was applied to areas with mucosal vascular lesions. Results: In total, 200 cirrhotic patients were enrolled; 12 patients were excluded due to death (n = 6) caused by hepatic encephalopathy (n = 3), hepatorenal syndrome (n = 2), or chronic lymphatic leukemia (n = 1), or did not complete the treatment sessions (n = 6), so 188 patients completed the study ...
Pagina nueva 1 1. Introduction Hepatopulmonary syndrome is a rare complication characterized by liver disease associated with intrapulmonary vascular dilatations and hypoxemia.1 A prevalence of 9-20% has been described in children associated with biliary duct atresia, 0.5% in patients with portal thrombosis2 and 2-8% in cirrhosis and portal hypertension.2,3 Although the condition is uncommon, it is important that the clinician recognizes this disease due its progressive nature.. 2. Clinical case We report the case of an 8-year-old girl without significant perinatal or respiratory history. At 3 of years of age she was diagnosed with liver cirrhosis of unknown etiology. She was hospitalized on multiple occasions due to upper gastrointestinal (GI) bleeding from large esophageal varices. She also had portal hypertension. She was under treatment with furosemide, spirinolactone, propanolol, omeprazole, lactulose and liver transplant protocol for which she presented to the pulmonary service for ...
"Calcium gluconate". Drug Information Portal. U.S. National Library of Medicine. Medicine portal. ... Hypertension. 15 (2): 149-152. doi:10.1161/01.hyp.15.2_suppl.i149. PMID 2404858. "FDA Drug Shortages". www.accessdata.fda.gov. ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ... Most of the blood is returned to the liver via the portal venous system for further processing and detoxification before ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ... such as hypertension, impaired glucose tolerance, diabetes mellitus, hyperlipidemia, and obstructive sleep apnea. A doctor- ... but the benefit for hypertension is uncertain. It is uncertain whether any given bariatric procedure is more effective than ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Portal hypertension. Portosystemic shunt. Pseudoaneurysm. Covered stent Surgical ligation with or without vascular bypass ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Portal hypertension *Transjugular intrahepatic portosystemic shunt [TIPS]. *Distal splenorenal shunt procedure. Gallbladder, ...
Singhal, D; Kakodkar, R; Soin, AS; Gupta, S; Nundy, S (Nov 2006). "Sinistral portal hypertension. A case report". JOP. 7 (6): ... Gupta, S; Singhal, A; Goyal, N; Vij, V; Wadhawan, M (Apr 2011). "Portal biliopathy treated with living-donor liver transplant: ... "Proximal splenorenal shunts for extrahepatic portal venous obstruction in children". Ann Surg. 219 (2): 193-6. doi:10.1097/ ...
Clinical presentations of portal hypertension include: A dilated inferior mesenteric vein may or may not be related to portal ... In portal hypertension, as in the case of cirrhosis of the liver, the anastomoses become congested and form venous dilatations ... "Surgicomania: Portal Hypertension". surgicomania.blogspot.co.uk. 2009-11-23. Retrieved 2016-08-12. Khader.O.Thabet, Mohammed Al ... "Clinicopathological Features and Treatment of Ectopic Varices with Portal Hypertension". International Journal of Hepatology. ...
Child CG, Turcotte JG (1964). "Surgery and portal hypertension". In Child CG (ed.). The liver and portal hypertension. ... MELD Score MELD-Plus The surgeon and portal hypertension expert Charles Gardner Child (1908-1991) (with Turcotte) of the ...
Gestational hypertension (or pregnancy-induced hypertension) and pre-eclampsia Methyldopa is capable of inducing a number of ... Medicine portal. ... "Methyldopa for primary hypertension". The Cochrane Database of ... Nonetheless, one of methyldopa's still current indications is in the management of pregnancy-induced hypertension (PIH), as it ... Methyldopa is used in the clinical treatment of the following disorders: Hypertension (or high blood pressure) ...
Current management of portal hypertension. Journal of gastrointestinal Surgery. 2005;9(7):992-1005. Sugiura M, and Futagawa S. ...
Hypertension, Dialysis & Clinical Nephrology (1997). "Nordiska Njurdagar (Nordic Nephrology Days)". Hypertension, Dialysis, and ... The Biotech/Life Sciences Portal. Archived from the original on 18 July 2011. Retrieved 3 October 2007. "About Reverse Vending ... Nils Alwall (1997). "Nils Alwall Lecture". Hypertension, Dialysis, and Clinical Nephrology. Retrieved 3 October 2007. Arvid ...
Hypertension, Dialysis & Clinical Nephrology (1997). "Nordiska Njurdagar (Nordic Nephrology Days)". Hypertension, Dialysis, and ... The Biotech/Life Sciences Portal. Archived from the original on July 18, 2011. Retrieved October 3, 2007. Lund University (2005 ... Nils Alwall (1997). "Nils Alwall Lecture". Hypertension, Dialysis, and Clinical Nephrology. Retrieved October 3, 2007. Arvid ... HDCN (2002). "Development of Hemodialysis: From Access to Machine". Hypertension, Dialysis, and Clinical Nephrology. Retrieved ...
Severtsev A. N. "Portal Hypertension" Overview. Klinicheskiy Vestnik, 1997, №3, p. 35-39. Shugurov V. A., Blohin A. P., Malov U ... 5. - p. 4-8. "Portal hypertension" (Severtsev A. N.). "Acute surgical diseases" (manuals for students of fifth-year and sixth- ... "Sclerotherapy of the varicose veins of the esophagus of the patients with portal hypertension" (Manuals). - 2005. p. 27. Brehov ...
Malignant hypertension[edit]. It could be useful for managing malignant hypertension due to end stage renal failure.[4] ... Madoff DC, Hicks ME, Vauthey JN, Charnsangavej C, Morello FA, Ahrar K, Wallace MJ, Gupta S (2002). "Transhepatic portal vein ... Patients who undergo cerebral embolization or portal vein embolization are usually given a general anesthetic. ... "Renal artery embolization for managing uncontrolled hypertension in a kidney transplant candidate". Avicenna J Med. 3 (1): 23- ...
Propranolol is the only agent indicated for control of tremor, portal hypertension, and esophageal variceal bleeding, and used ... Cleophas, Ton (1995). Beta-blockers in hypertension and angina pectoris: different compounds, different strategies. Kluwer ... Manger WM, Gifford RW (2001). 100 Questions and Answers about Hypertension. Blackwell Science. p. 106. ISBN 978-0-632-04481-8. ... Hypertension[16], although they are generally not preferred as an initial treatment.[23] ...
In portal hypertension, venous resistance is increased within the portal venous system; when the pressure in the portal venous ... has been shown to alleviate varices caused by portal hypertension. Successful treatment of portal hypertension that ... Typically this occurs due to portal hypertension which shunts venous blood from the portal system through the portosystemic ... Haemorrhoids occur due to prolapse of the rectal venous plexus and are no more common in patients with portal hypertension than ...
"Noncirrhotic presinusoidal portal hypertension associated with chronic arsenical intoxication". Gastroenterology. 68 (5 Pt 1): ...
They also have an effect on cardiomyopathy, postural orthostatic tachycardia syndrome and portal hypertension, to name a few. ... Tripathi, D; Hayes, PC (October 2013). "Beta blockers in portal hypertension: new developments and controversies". Liver ... with the emphasis on differentiating pre-existing hypertension from pregnancy induced hypertension (gestational and the ... Hypertension is reported to complicate one out of ten pregnancies, which makes it the most common medical disorder in pregnancy ...
Leo's College, Kyegobe, in Fort Portal, Kabarole District for his O-Level studies. He then joined the Catholic brotherhood, ... He also suffered from diabetes mellitus and systemic hypertension. Bantariza was born in Mitooma District in Uganda's Western ...
August 2001). "Human hypertension caused by mutations in WNK kinases". Science. 293 (5532): 1107-12. doi:10.1126/science. ... HumanProteinAtlas/WNK4 GeneCard/WNK4 UniProt/WNK4 OMIM/WNK4 Biology portal. ... Arnold JE, Healy JK (September 1969). "Hyperkalemia, hypertension and systemic acidosis without renal failure associated with a ... Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW (November 1970). "Hypertension and severe hyperkalaemia associated with ...
Anti-centromere antibodies often correlate with developing portal hypertension. Anti-np62 and anti-sp100 are also found in ... Stage 1 - portal stage: Normal-sized triads, portal inflammation, subtle bile duct damage: Granulomas are often detected in ...
Anorectal varices due to increased portal hypertension (blood pressure in the portal venous system) may present similar to ... Portal hypertension does not increase the risk of hemorrhoids. A number of preventative measures are recommended, including ...
... such as hypertension, high cholesterol, and microalbuminuria, improves a person's life expectancy.[25] Decreasing the systolic ... Several diets may be effective such as the Dietary Approaches to Stop Hypertension (DASH), Mediterranean diet, low-fat diet, or ...
Mendelian inheritance was rediscovered at the beginning of the 20th century. As Mendel's ideas spread, geneticists began to connect Mendel's rules of inheritance of single factors to Darwinian evolution. For early geneticists, it was not immediately clear that the smooth variation in traits like body size (i.e., Incomplete Dominance) was caused by the inheritance of single genetic factors. Although Darwin himself observed that inbred features of fancy pigeons were inherited in accordance with Mendel's laws (although Darwin didn't actually know about Mendel's ideas when he made the observation), it was not obvious that these features selected by fancy pigeon breeders can similarly explain quantitative variation in nature.[5] An early attempt by William Ernest Castle to unify the laws of Mendelian inheritance with Darwin's theory of speciation invoked the idea that species become distinct from one another as one species or the other acquires a novel Mendelian factor.[6] Castle's conclusion was ...
... due to general hypertension) tends to increase the duration of spontaneous epistaxis.[7] Anticoagulant medication and disorders ... "Is epistaxis evidence of end-organ damage in patients with hypertension?". Laryngoscope. 109 (7): 1111-1115. doi:10.1097/ ...
Glaucoma / Ocular hypertension / Primary juvenile glaucoma. *Floater. *Leber's hereditary optic neuropathy. *Red eye ...
Combination of levothyroxine with ketamine may cause hypertension and tachycardia;[25] and tricyclic and tetracyclic ... U.S. National Library of Medicine: Drug Information Portal - Levothyroxine. *v. *t ...
Mangum K, Partna L, Vavrek D (2012). "Spinal manipulation for the treatment of hypertension: a systematic qualitative ... Medicine portal. *List of topics characterized as pseudoscience. *Chiropractic education. *Chiropractic schools ... found insufficient low bias evidence to support the use of spinal manipulation as a therapy for the treatment of hypertension.[ ...
... which can lead to difficulty with breathing and/or pulmonary hypertension. Cardiorespiratory complications may arise, which is ...
"Hypertension. 63 (4): 878-85. doi:10.1161/HYP.0000000000000003. PMID 24243703. Archived from the original on 20 November 2013. ... Viruses portal. *Aniru Conteh. *Lujo virus. References[edit]. *^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ...
... concerns the diagnosis and treatment of kidney diseases, including electrolyte disturbances and hypertension, and ... such as renal osteodystrophy and hypertension. A physician who has undertaken additional training and become certified in ... hypertension, and disorders of acid/base or electrolytes. ... Community portal. *Recent changes. *Contact page. Tools. *What ...
Clinical and Experimental Hypertension. Part A, Theory and Practice, 7(7), 907-932. ... DeQuattro, V., & Hamad, R. (1985). The role of stress and the sympathetic nervous system in hypertension and ischemic heart ... such as smoking and hypertension, increases the risk of coronary heart disease over the course of the next three and a half ...
Hypertension has been reported to occur very rarely with moclobemide therapy.[12] ...
He suffered from hypertension,[82] and became almost completely blind in 1973. Sartre was a notorious chain smoker, which could ... Biography portal. *Sartre's Roads to Freedom Trilogy. *Situation (Sartre). *Freud: The Secret Passion ...
Intracranial hypertension *Hydrocephalus. *Normal pressure hydrocephalus. *Choroid plexus papilloma. *Idiopathic intracranial ...
... inflammatory ocular hypertension syndrome (IOHS); 2) severe uveitic angle closure; 3) corticosteroid-induced; and 4) a ...
It is strongly associated with smoking, hypertension, and diabetes.[2] Diagnosis[edit]. Intermittent claudication is a symptom ... Medicines that control lipid profile, diabetes, and hypertension may increase blood flow to the affected muscles and allow for ... Portal vein thrombosis. *Renal vein thrombosis. *upper limb / torso *Mondor's disease. *Paget-Schroetter disease ...
... presenting some of the characteristics of portal vein thrombosis and portal hypertension, but localized to part of the ... which drains in the splenic vein shortly before the origin of the hepatic portal vein. The splenic vein ends in the portal vein ... These include varices in the stomach wall due to hypertension in the short gastric veins and abdominal pain. This results in ... The splenic vein, here called the "lienal vein", travels from the spleen, above the pancreas, and ends in the portal vein. ...
Perhaps the most difficult aspect of membranous glomerulonephritis is deciding which people to treat with immunosuppressive therapy as opposed to simple "background" or anti-proteinuric therapies. A large part of this difficulty is due to a lack of ability to predict which people will progress to end-stage kidney disease, or kidney disease severe enough to require dialysis. Because the above medications carry risk, treatment should not be initiated without careful consideration as to risk/benefit profile. Of note, corticosteroids (typically Prednisone) alone are of little benefit. They should be combined with one of the other 5 medications, each of which, along with prednisone, has shown some benefit in slowing down progression of membranous nephropathy. It must be kept in mind, however, that each of the 5 medications also carry their own risks, on top of prednisone. The twin aims of treating membranous nephropathy are first to induce a remission of the nephrotic syndrome and second to prevent ...
Forced expiratory flow (FEF) is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. It can be given at discrete times, generally defined by what fraction remains of the forced vital capacity (FVC). The usual intervals are 25%, 50% and 75% (FEF25, FEF50 and FEF75), or 25% and 50% of FVC. It can also be given as a mean of the flow during an interval, also generally delimited by when specific fractions remain of FVC, usually 25-75% (FEF25-75%). Average ranges in the healthy population depend mainly on sex and age, with FEF25-75% shown in diagram at left. Values ranging from 50-60% and up to 130% of the average are considered normal.[11] Predicted normal values for FEF can be calculated online and depend on age, sex, height, mass and ethnicity as well as the research study that they are based on. MMEF or MEF stands for maximal (mid-)expiratory flow and is the peak of expiratory flow as taken from the flow-volume curve and measured in liters per second. ...
Portal hypertension. *Nutmeg liver. *Alcoholic liver disease. *Liver failure *Hepatic encephalopathy. *Acute liver failure ...
Hypertension Vol2. No 1. *^ a b c NDA 19-922/S-005: Corlopam RA06497-R1-9/03 brand of Fenoldopam Mesylate Injection, USP ...
Inhaled bronchodilators are the primary medications used,[2] and result in a small overall benefit.[121] The two major types are β2 agonists and anticholinergics; both exist in long-acting and short-acting forms.[122] They reduce shortness of breath, wheeze, and exercise limitation, resulting in an improved quality of life.[123] It is unclear if they change the progression of the underlying disease.[2] In those with mild disease, short-acting agents are recommended on an as needed basis.[2] In those with more severe disease, long-acting agents are recommended.[2] Long-acting agents partly work by reducing hyperinflation.[74] If long-acting bronchodilators are insufficient, then inhaled corticosteroids are typically added.[2] Which type of long-acting agent, long-acting muscarinic antagonist (LAMA) such as tiotropium or a long-acting beta agonist (LABA) is better is unclear, and trying each and continuing with the one that works best may be advisable.[124] Both types of agent appear to reduce ...
When hypertension is caused by OSA, it is distinctive in that, unlike most cases (so-called essential hypertension), the ... Diastolic function of the heart also becomes affected.[53] Elevated arterial pressure (i.e., hypertension) can be a consequence ... Conclusion: Sleep apnoea syndrome is profoundly associated with hypertension independent of all relevant risk factors.. CS1 ... We found a dose-response association between sleep-disordered breathing at base line and the presence of hypertension four ...
The compound 13-cis retinoic acid was first studied in the 1960s at Roche Laboratories in Switzerland by Werner Bollag as a treatment for skin cancer. Experiments completed in 1971 showed that the compound was likely to be ineffective for cancer and, surprisingly, that it could be useful to treat acne. However, they also showed that the compound was likely to cause birth defects, so in light of the events around thalidomide, Roche abandoned the product. In 1975, Gary Peck and Frank Yoder independently rediscovered the drug's use as a treatment of cystic acne while studying it as a treatment for lamellar ichthyosis, and published that work. Roche resumed work on the drug. In clinical trials, subjects were carefully screened to avoid including women who were or might become pregnant. Roche's New Drug Application for isotretinoin for the treatment of acne included data showing that the drug caused birth defects in rabbits. The FDA approved the application in 1982. Scientists involved in the ...
"Role of extracellular superoxide dismutase in hypertension". Hypertension. 48 (3): 473-81. doi:10.1161/01.HYP.0000235682.47673. ... "Hypertension. 55 (2): 277-83, 6p following 283. doi:10.1161/HYPERTENSIONAHA.109.142646. PMC 2813894. PMID 20008675.. ... In mice, the extracellular superoxide dismutase (SOD3, ecSOD) contributes to the development of hypertension.[40][41] ... "Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central ...
Ocular hypertension. References[edit]. *^ Cassin, B. and Solomon, S. Dictionary of Eye Terminology. Gainesville, Florida: Triad ... "A lymphatic defect causes ocular hypertension and glaucoma in mice". The Journal of Clinical Investigation. 124: 4320-24. doi ...
It should be distinguished from renovascular hypertension, which is a form of secondary hypertension, and thus has opposite ... Glomerular hypertension and glomerular hyperfiltration[edit]. An alternative mechanism of hypertensive nephropathy is prolonged ... In the kidneys, as a result of benign arterial hypertension, hyaline (pink, amorphous, homogeneous material) accumulates in the ... See also: Management of hypertension. The aim of the medical treatment is to slow the progression of chronic kidney disease by ...
A urinary tract infection (UTI) is an infection that affects part of the urinary tract.[1] When it affects the lower urinary tract it is known as a bladder infection (cystitis) and when it affects the upper urinary tract it is known as a kidney infection (pyelonephritis).[9] Symptoms from a lower urinary tract infection include pain with urination, frequent urination, and feeling the need to urinate despite having an empty bladder.[1] Symptoms of a kidney infection include fever and flank pain usually in addition to the symptoms of a lower UTI.[9] Rarely the urine may appear bloody.[6] In the very old and the very young, symptoms may be vague or non-specific.[1][10] The most common cause of infection is Escherichia coli, though other bacteria or fungi may rarely be the cause.[2] Risk factors include female anatomy, sexual intercourse, diabetes, obesity, and family history.[2] Although sexual intercourse is a risk factor, UTIs are not classified as sexually transmitted infections (STIs).[11] ...
Specific radiologic signs (pneumatosis intestinalis or portal venous air). *Laboratory changes (metabolic acidosis, too few ... Portal hypertension. *Nutmeg liver. *Alcoholic liver disease. *Liver failure *Hepatic encephalopathy. *Acute liver failure ...
Intracranial hypertension *Hydrocephalus/NPH. *Choroid plexus papilloma. *Idiopathic intracranial hypertension. *Cerebral edema ...
Voorhees, A.B., Price, J.B.: Extrahepatic portal hypertension. Arch Surg. 108: 338, 1974.PubMedCrossRefGoogle Scholar ... Portal Hypertension Esophageal Varix Variceal Hemorrhage Portacaval Shunt Splenorenal Shunt These keywords were added by ... Pinkerton, J.A., Holcomb, G.W., Foster, J.H.: Portal hypertension in childhood. Ann. Surg. 175:870, 1972.Google Scholar ... Turrill, F.L., Mikkelsen, W.P.: "Sinistral" (left sided) extrahepatic portal hypertension. Arch. Surg 99: 365, 1969.PubMed ...
Ultrasonic diagnosis of portal hypertension. Br Med J (Clin Res Ed) 1983; 287 :1299 ... Ultrasonic diagnosis of portal hypertension.. Br Med J (Clin Res Ed) 1983; 287 doi: https://doi.org/10.1136/bmj.287.6401.1299-b ...
Endoscopy plays a central role in the management of portal hypertension contributing to: early detection of esophageal and ... Endoscopy in the management of portal hypertension. In: Groszmann R.J., Bosch J. (eds) Portal Hypertension in the 21st Century ... Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology. 1998;28:868-80.PubMedCrossRefGoogle ... French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol. 1999;11:741-5.PubMedCrossRefGoogle ...
portal hypertension. Your portal vein carries blood from your stomach, intestines, spleen, gallbladder, and pancreas to your ... Can primary biliary cholangitis (PBC) cause portal hypertension?. ANSWER If primary biliary cholangitis (formerly known as ... Scar tissue from cholangitis blocks normal circulation and can boost pressure in your portal vein. ...
PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Portal Hypertension ... Portal Hypertension: Pathophysiology 8Figure 3: Portal Hypertension: Prehepatic Causes 9Figure 4: Portal Hypertension: Hepatic ... Portal Hypertension Therapeutics Pipeline 50Table 30: Portal Hypertension Therapeutics, Global, Deals, 2011 51 ... 498.2.2 Dong-A Pharmaceutical Co Ltd (Dong-A) 509 Portal Hypertension Therapeutics - Deals 5110 Portal Hypertension ...
Care guide for Portal Hypertension. Includes: possible causes, signs and symptoms, standard treatment options and means of care ... What is portal hypertension?. Portal hypertension is high blood pressure in the portal vein of your liver. Your portal vein is ... How is portal hypertension treated?. *Beta-blockers lower the blood pressure in your portal vein by slowing your heart rate and ... Family history of portal hypertension, or a narrowed portal vein at birth ...
Hydatid Cysts of Liver and Portal Hypertension. Ali Emre,1,2 Orhan Arioğul,1 Aydin Alper,1 Attilâ Ökten,1 Ali Uras,1 and ... Two cases of portal hypertension due to hydatid cysts of the liver are reported. In one of the patients, symptoms were ... Therefore hydatidosis should be remembered amongst the causes of portal hypertension in countries where the disease is endemic. ... The other patient was operated on with a diagnosis of extrahepatic presinusoidal portal hypertension caused by extrinsic ...
WHAT are the options for portal hypertension? Dr. Kevn Hsu of Austin Texas only has Ricky on Naldolol to keep the pressure down ... PORTAL HYPERTENSION - VEIN STOMACH. WHAT are the options for portal hypertension? Dr. Kevn Hsu of Austin Texas only has Ricky ... Yes Nadolol is the appropriate treatment for portal hypertension. Portal hypertension is a complication of cirrhosis. It is not ... Yes Nadolol is the appropriate treatment for portal hypertension. Portal hypertension is a complication of cirrhosis. It is not ...
This causes portal hypertension.. Portal hypertension is different from the high blood pressure (systemic hypertension) that ... Portal Hypertension. Portal hypertension is high blood pressure in the veins that filter blood from the intestines through the ... In the United States, cirrhosis is the most common cause of portal hypertension. Normally, blood from the spleen and intestines ... Read our Portal Hypertension encyclopedia resources online. ... pressure may build up in the portal vein. ...
39 patients with portal hypertension experience fatigue, depressed mood, pain, anxious mood, and insomnia and use Gabapentin, ... Find the most comprehensive real-world symptom and treatment data on portal hypertension at PatientsLikeMe. ... Lisinopril, Nadolol, and Psychiatric evaluation to treat their portal hypertension and its symptoms. ... What is portal hypertension?. Portal hypertension is high blood pressure in the portal vein and associated veins that flow into ...
Portal Hypertension answers are found in the 5-Minute Clinical Consult powered by Unbound Medicine. Available for iPhone, iPad ... Portal Hypertension is a topic covered in the 5-Minute Clinical Consult. To view the entire topic, please sign in or purchase a ... Portal Hypertension. In: Stephens MB, Golding J, Baldor RA, et al, eds. 5-Minute Clinical Consult. 27th ed. Wolters Kluwer; ... Portal Hypertension. (2019). In Stephens, M. B., Golding, J., Baldor, R. A., & Domino, F. J. (Eds.), 5-Minute Clinical Consult ...
Portal hypertension is a condition in which the liver does not get enough blood because of high blood pressure in the portal ... Portal hypertension is a condition in which the liver does not receive enough blood due to high blood pressure of the portal ... Other possible causes of portal hypertension are hepatitis C and thrombosis, or blood clots of the portal veins. ... The majority of portal hypertension cases are due to other disorders or conditions that cause damage to the liver. One of the ...
Find best Hepatologists for Portal Hypertension near you & make an appointment online instantly! Portal Hypertension ... Portal Hypertension Doctors Near You. Need to make a doctor appointment for Portal Hypertension this week? Use Zocdoc to find ...
Find information on portal hypertension symptoms, causes, treatments and the TIPS procedure. ... Learn about portal hypertension from the Cleveland Clinic. ... Portal Hypertension Portal hypertension is an increase in the ... What is portal hypertension?. Portal hypertension is an increase in the pressure within the portal vein (the vein that carries ... What causes portal hypertension?. The most common cause of portal hypertension is cirrhosis, or scarring of the liver. ...
Probiotics for Portal Hypertension. The recruitment status of this study is unknown. The completion date has passed and the ... Hypertension, Portal. Propranolol. Norfloxacin. Adrenergic beta-Antagonists. Adrenergic Antagonists. Adrenergic Agents. ... Consecutive patients of cirrhosis with portal hypertension who fulfill the following criteria:. *Diagnosed cases of cirrhosis ( ... Consecutive patients of cirrhosis with portal hypertension who fulfill the following criteria:. *Diagnosed cases of cirrhosis ( ...
Portal Hypertension. Portal hypertension is high blood pressure of the portal vein. The portal vein is located in your abdomen ... and endoscopic exams to see if you have portal hypertension. Treatment. Healthcare providers treat portal hypertension in ... your healthcare provider may treat portal hypertension with shunting. This involves putting stents in the portal vein to open ... When you have portal hypertension, the increased pressure means it is harder for the blood from the liver to flow through the ...
Probiotics for Portal Hypertension. The safety and scientific validity of this study is the responsibility of the study sponsor ... Hypertension, Portal. Propranolol. Norfloxacin. Adrenergic beta-Antagonists. Adrenergic Antagonists. Adrenergic Agents. ... Consecutive patients of cirrhosis with portal hypertension who fulfill the following criteria:. *Diagnosed cases of cirrhosis ( ... Consecutive patients of cirrhosis with portal hypertension who fulfill the following criteria:. *Diagnosed cases of cirrhosis ( ...
... V. K. Snowdon,1 N. Guha,2 and J. A. Fallowfield1 ... Harry Sutton, Anil Dhawan, and Tassos Grammatikopoulos, "Non-invasive Markers of Portal Hypertension," Journal of Pediatric ... "Portal Hypertension as Immune Mediate Disease," Hepatitis Monthly, vol. 14, no. 5, 2014. View at Publisher · View at Google ... correlates with portal hypertension in patients with alcoholic cirrhosis," Scandinavian Journal of Gastroenterology, pp. 1-9, ...
Care guide for Portal Hypertension (Discharge Care). Includes: possible causes, signs and symptoms, standard treatment options ... Portal hypertension is high blood pressure in the portal vein of your liver. Your portal vein is the main blood supply for your ... Manage portal hypertension:. *Limit sodium (salt) as directed. Too much sodium can affect your fluid balance. Check labels to ... Beta-blockers lower the blood pressure in your portal vein. This is done by slowing your heart rate and making your blood ...
Portal Hypertension. One consequence of chronic liver disease can be portal hypertension. This is an increase in the blood ... Symptoms of portal hypertension. Portal hypertension and its consequence of bleeding varices are usually seen in people with ... As a result, the pressure in the portal vein rises. This is known as portal hypertension. ... Treatment for Portal Hypertension Current treatments do allow for early identification of those people who are at risk of ...
DAmico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995 Jul. 22(1):332- ... encoded search term (What are the dynamic factors that account cause portal hypertension in cirrhosis?) and What are the ... What are the dynamic factors that account cause portal hypertension in cirrhosis?. Updated: Jul 30, 2018 ... dynamic factors that account cause portal hypertension in cirrhosis? What to Read Next on Medscape. Related Conditions and ...
Two important factors-vascular resistance and blood flow-exist in the development of portal hypertension. ... Many conditions are associated with portal hypertension, with cirrhosis being the most common cause of this disorder. ... Portal Hypertension) and Portal Hypertension What to Read Next on Medscape. Related Conditions and Diseases. * Hypertension ... Findings suggestive of portal hypertension include collaterals arising from the portal system and dilatation of the inferior ...
Information on portal hypertension or high blood pressure in children including causes, symptoms and treatment from St. Louis ... Portal hypertension may be due to increased blood pressure in the portal blood vessels, or resistance to blood flow through the ... Portal hypertension is abnormally high blood pressure in the portal vein, which supplies the liver with blood from the ... Portal hypertension can lead to the growth of new blood vessels (called collaterals) that connect blood flow from the intestine ...
3 Abstracts with Hypertension: Portal Research. Filter by Study Type. Animal Study. ... Cordyceps mycelia may decrease portal hypertension in rats with chemically induced liver cirrhosis. Nov 01, 2008. ... In patients with moderate to severe portopulmonary hypertension, beta-blockers are associated with significant worsening in ...
... an open-label Phase 2 a trial evaluating the effects of obeticholic acid for the treatment of portal hypertension. ... About Portal Hypertension. Portal hypertension results from increased pressure in the portal vein, which feeds most of the ... for the treatment of portal hypertension. Twelve patients with established alcoholic cirrhosis and portal hypertension were ... Clinically significant portal hypertension is defined as an HVPG ,10 mm Hg (1 mm to 5 mm HVPG is normal). It is a common cause ...
Emergency Endoscopy after Gastrointestinal Haemorrhage in 50 Patients with Portal Hypertension Br Med J 1974; 4 :94 ... Emergency Endoscopy after Gastrointestinal Haemorrhage in 50 Patients with Portal Hypertension. Br Med J 1974; 4 doi: https:// ...
Learn about portal hypertensions symptoms & treatment, including TIPS. Our researchers are also testing new drug combinations ... Liver Transplantation for Portal Hypertension. If your portal hypertension cannot be effectively treated through other means ... Procedures to Relieve Portal Hypertension. The doctors at NewYork-Presbyterian offer a range of procedures to treat portal ... In people with portal hypertension, there is increased pressure in the portal vein-the major vein transporting blood through ...
Pathophysiology of portal hypertension and variceal bleeding. Download Prime PubMed App to iPhone, iPad, or Android ... Esophageal and Gastric VaricesGastrointestinal HemorrhageHumansHypertension, PortalPortal SystemSplanchnic CirculationVascular ... Portal hypertension results from an interaction of abnormal intrahepatic resistance and increases in portal blood flow. ... The rupture of esophageal varices is a devastating complication of portal hypertension. Increased portal pressure is necessary ...
Portal Hypertension Accessed 6/11/2018.. *Miñano C, MD, Garcia-Tsao, G. Portal Hypertension. Gastroenterol Clin North Am. 2010 ... How is portal hypertension diagnosed?. Endoscopic examination, X-ray studies, and lab tests can confirm that you have variceal ... you will have the following tests to determine the extent and severity of your portal hypertension:. *Evaluation of your ...
... Respiration. 1994;61(2):117-9. doi: 10.1159/000196320. ... To our knowledge, only one case of sarcoidosis with combined portal and pulmonary hypertension has previously been described. ... The further course was characterized by progressive chronic intrahepatic cholestasis and portal hypertension. Right heart ...
  • Ascites, another important complication of advanced cirrhosis and severe portal hypertension, is sometimes refractory to treatment and is complicated by spontaneous bacterial peritonitis and hepatorenal syndrome. (cmaj.ca)
  • We describe the pathophysiology of portal hypertension and the current management of its complications, with emphasis on the prophylaxis and treatment of variceal bleeding and ascites. (cmaj.ca)
  • Ascites and pedal edema are sometimes the earliest manifestations of portal hypertension. (clinicaladvisor.com)
  • Nevertheless, in a few well documented cases, transient portal hypertension has induced transient ascites [1] and bleeding esophageal varices [2,3]. (springer.com)
  • Valla D, Fléjou JF, Lebrec D, Bernuau J, Rueff B, Salzmann JL, Benhamou JP (1989) Portal hypertension and ascites in acute hepatitis: Clinical hemodynamic and histological correlations. (springer.com)
  • Highly effective in lowering portal pressure gradients in patients with refractory ascites and variceal bleeding, the GORE® VIATORR® TIPS Endoprosthesis effectively treats patients over a longer period of time. (goremedical.com)
  • citation needed] Signs and symptoms of portal hypertension include: Ascites (free fluid in the peritoneal cavity), Abdominal pain or tenderness (when bacteria infect the ascites, as in spontaneous bacterial peritonitis). (wikipedia.org)
  • Quantitative modeling of the physiology of ascites in portal hypertension. (biomedsearch.com)
  • Although the factors involved in cirrhotic ascites have been studied for a century, a number of observations are not understood, including the action of diuretics in the treatment of ascites and the ability of the plasma-ascitic albumin gradient to diagnose portal hypertension. (biomedsearch.com)
  • Important studies, mostly prospective, regarding the management of the complications of portal hypertension are reviewed, including a trial of β-blockers in the prevention of varices, a randomized trial of endoscopic variceal ligation plus nadolol in preventing recurrent variceal bleeding and several meta-analyses on trials comparing large-volume paracentesis with transjugular intrahepatic portosystemic shunt in the management of refractory ascites. (ovid.com)
  • Introducing a new series of monographs, Dr. Child's editorial effort provides an interesting account of the history of our knowledge of the portal circulation, reviews current concepts of the pathophysiology of portal hypertension, briefly discusses technical aspects of surgery of the portal system, and outlines available approaches for management of the major complications of an elevated portal pressure: esophageal varices, ascites, and hepatic encephalopathy. (annals.org)
  • In patients with advanced liver disease with portal hypertension, portal-systemic collaterals contribute to circulatory disturbance, gastrointestinal hemorrhage, hepatic encephalopathy, ascites, hepatopulmonary syndrome and portopulmonary hypertension. (elsevier.es)
  • Complications of portal hypertension are major concerns in liver cirrhosis and significant morbidity and mortality mainly because of variceal bleeding, ascites, bacterial infections, hepatic encephalopathy, and hepatorenal syndrome. (koreamed.org)
  • In view of the discrepancies in findings, a Doppler ultrasonography was performed, which showed an aliasing phenomenon in the right lobe of the liver, with high velocity flow in the right branch of the portal vein, splenomegaly and ascites ( Fig. 1 a). (elsevier.es)
  • Ascites develops secondary to portal hypertension and low albumin concentrations. (merckvetmanual.com)
  • Rarely, arterialization of the hepatic parenchyma by an intrahepatic arteriovenous malformation leads to arterialization of the intrahepatic circulation and causes portal hypertension and ascites. (merckvetmanual.com)
  • Transjugular intrahepatic portosystemic shunts (TIPS) are known to be efficacious in reducing portal venous pressure and control of complications secondary to portal hypertension such as variceal bleeding and ascites. (sages.org)
  • This is an important issue, because portal hypertension can result in bleeding from varicose veins in the oesophagus or the development of ascites, or abdominal dropsy. (medicalxpress.com)
  • In these cases there is portal hypertension, splenomegaly and ascites but NO hepatomegaly. (brainscape.com)
  • The consensus itself is based on the Baveno III consensus with regard to portal hypertensive bleeding and the suggestions of the International Ascites Club regarding the treatment of ascites. (springermedizin.at)
  • Stanley, A.J. , Bouchier, L.A.D. and Hayes, P.C. (1997) Pathophysiology and management of portal hypertension 2: cirrhotic ascites. (gla.ac.uk)
  • Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. (medscape.com)
  • It can also demonstrate portal flow and helps in diagnosing cavernous transformation of the portal vein, portal vein thrombosis, and splenic vein thrombosis. (medscape.com)
  • Splenic vein or portal vein thrombosis may lead to the development of gastrointestinal bleeding secondary to varices while having few other signs or symptoms. (oncologynurseadvisor.com)
  • Extraheptic causes include portal or splenic vein thrombosis (also pre-hepatic) and hepatic vein thrombosis (also post-hepatic). (clinicaladvisor.com)
  • Other causes include: Prehepatic causes Portal vein thrombosis Splenic vein thrombosis Arteriovenous fistula (increased portal blood flow) Splenomegaly and/or hypersplenism (increased portal blood flow) Hepatic causes Cirrhosis of any cause. (wikipedia.org)
  • Portal vein thrombosis (extra-hepatic portal hypertension), for example, may present within the first five years of life as a major haematemesis with only splenomegaly and a reduced platelet count as clues to the diagnosis. (pediatriconcall.com)
  • Complication occurred in 14 patients in the TIPS group including re-bleeding (n=5), encephalopathy (n=4), ascite (n=2), bleeding from a pseudoaneurysm of the thoracoabdominal aorta (n=2) and Pulmonary infection (n=1, 1.8%) as compared with 5 patients in the LS group including pulmonary effusion (n=1), pancreatic leakage (n=1) and portal vein thrombosis (n=3). (sages.org)
  • Children may develop portal hypertension if they have a blockage of the portal vein outside of a healthy liver, called extra-hepatic portal vein thrombosis. (childrenscolorado.org)
  • Prehepatic causes include portal vein thrombosis or congenital atresia. (thefullwiki.org)
  • Ottinger, L.W., Moncure, A.C.: Transthoracic ligation of bleeding esophageal varices in patients with intrahepatic portal obstruction. (springer.com)
  • and treatment of acute variceal bleeding, portal hypertensive gastropathy (PHG), and ectopic varices. (springer.com)
  • Increased pressure in the portal vein causes large veins ( varices ) to develop across the esophagus and stomach to get around the blockage. (clevelandclinic.org)
  • Portal hypertension and its consequence of bleeding varices are usually seen in people with moderately advanced liver disease. (britishlivertrust.org.uk)
  • One manifestation of portal hypertension is the development of esophageal varices, which are distended and weakened veins in the lower part of the esophagus that can burst and cause catastrophic bleeding. (cnbc.com)
  • The end result of these interactions is the development of increased portal pressure and portosystemic collaterals, the most important of which are esophageal varices. (unboundmedicine.com)
  • The rupture of esophageal varices is a devastating complication of portal hypertension. (unboundmedicine.com)
  • Increased portal pressure is necessary for the development and rupture of varices but apparently not sufficient, because many patients with elevated portal pressures never bleed. (unboundmedicine.com)
  • Lowering portal pressure, reducing varix size, and supporting varices in scar tissue may all lower the risk of hemorrhage. (unboundmedicine.com)
  • Treatment consists of pharmacologic therapy to decrease portal pressure, endoscopic treatment of varices (band ligation or sclerotherapy) to treat variceal bleeding, and creation of a transjugular intrahepatic portosystemic shunt (TIPS) to reduce portal pressure if drug therapy and endoscopic treatment fail. (cmaj.ca)
  • Most patients with portal hypertension who present with acute gastrointestinal bleeding have cirrhosis and esophageal varices. (clinicaladvisor.com)
  • Treatments for portal hypertension aim to reduce pressure and to prevent complications, particularly controlling and preventing bleeding from varices. (columbiasurgery.org)
  • Shunting, or placement of tiny tubes, to provide sufficient blood flow around the liver, reduce portal hypertension, and prevent varices. (columbiasurgery.org)
  • Hearta W, Palmer ED (1959) Portal hypertension with esophageal varices in acute infectious hepatitis: further observations. (springer.com)
  • Increased spleen size (splenomegaly), which may lead to lower platelet counts (thrombocytopenia) Anorectal varices[citation needed] Swollen veins on the anterior abdominal wall (sometimes referred to as caput medusae) In addition, a widened (dilated) portal vein as seen on a CT scan or MRI may raise the suspicion about portal hypertension. (wikipedia.org)
  • Recent study results showed that cholangitis episodes and the presence of portal hypertension or gastroesophageal varices in adolescence may predict the need for liver transplantation in adulthood among pediatric patients with biliary atresia. (healio.com)
  • In this report, we present a case of isolated liver tuberculosis (TB) as a cause of non-cirrhotic portal hypertension leading to bleeding esophageal varices. (ajtmh.org)
  • With portal hypertension, blood backs up in nearby veins in the esophagus and stomach, causing varices. (brighamandwomens.org)
  • The most common manifestations of portal hypertension are esophageal and gastric varices. (pediatriconcall.com)
  • Thus not all bleeding in portal hypertension is due to varices but can also be due to portal hypertensive polyps. (pediatriconcall.com)
  • Acute bleeding from ruptured gastric varices (enlarged veins), the most severe consequence of portal hypertension (that is increased pressure in the veins leading to the liver), is associated with high death rates. (cochrane.org)
  • In people with portal hypertension , gastric varices are less prevalent than oesophageal varices. (cochrane.org)
  • Because of the potential severity of portal hypertension, including death from hemorrhaging esophageal varices, the FDA has revised the Warning and Precautions section of the Videx and Videx EC drug label to assure safe use of the medication. (empr.com)
  • Portal hypertension can lead to the growth of new blood vessels called varices that connect blood flow from the GI tract, such as the intestine, to the general circulation, bypassing the liver. (childrenscolorado.org)
  • Varices form when the body senses the increased portal vein pressure and tries to compensate. (childrenscolorado.org)
  • Why some patients with portal hypertension develop primarily esophageal varices and others, hypertensive gastropathy, remains unclear. (acpjc.org)
  • The rationale for the PESTO trial is based on previously obtained results in an animal model of cirrhosis, demonstrating that five days of OCA therapy can reverse portal hypertension via a local nitric oxide induced mechanism with no concomitant change in systemic blood pressure [Hepatology 2009, Vol 50, 74A]. (cnbc.com)
  • A research group led by hepatologists Mattias Mandorfer and Karin Kozbial of MedUni Vienna's Department of Gastroenterology and Hepatology have now demonstrated that portal vein hypertension also diminishes once the viral infection is healed. (medicalxpress.com)
  • The research group headed by Peter Ferenci, Harald Hofer and Markus Peck-Radosavljevic of the Department of Gastroenterology and Hepatology have conducted portal vein pressure measurements on patients who have recovered with interferon-free treatment and, using a new method similar to ultrasound, they have observed that portal vein hypertension diminishes in the majority of patients, so long as hepatitis C has been treated at an early stage. (medicalxpress.com)
  • Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension, Journal of Hepatology (2016). (medicalxpress.com)
  • In November 2004, the Austrian Society of Gastroenterology and Hepatology (ÖGGH) held for the first time a consensus meeting on the definitions and treatment of portal hypertension and its complications in the Billroth-Haus in Vienna, Austria (Billroth I-Meeting). (springermedizin.at)
  • Portal hypertension is a major complication of liver disease that results from a variety of pathologic conditions that increase the resistance to the portal blood flow into the liver. (nih.gov)
  • Portal hypertension is a complication of cirrhosis. (medhelp.org)
  • Pancytopenia can result from hypersplenism, a common complication in patients with portal hypertension. (medscape.com)
  • Although portal hypertension, the most significant complication for patients with liver cirrhosis, can become life-threatening, doctors do not have many effective treatment options available to them. (psmag.com)
  • In most cases, portal hypertension is a chronic complication of a chronic disease of the portal vein, or the liver, or the hepatic veins. (springer.com)
  • Portal hypertension is a complication secondary to cirrhosis that is characterized by increased blood flow and/or vascular resistance in the portal system, causing the appearance of a hyperdynamic collateral circulation. (scielo.br)
  • Portal hypertension is the main complication of cirrhosis and represents a leading cause of death in patients with chronic liver disease. (portlandpress.com)
  • we will provide real clinical cases in which the first clinical manifestation was a portal hypertension related complication in both cirrhosis and non-cirrhosis etiology. (easl.eu)
  • The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb ) may cause non-cirrhotic portal hypertension, a rare but serious complication. (empr.com)
  • Between January 2009 and March 2012, we enrolled 83 patients (55 with TIPS and 28 with LS plus EVL) with portal hypertension and a history of gastro-esophageal variceal rebleeding secondary to liver cirrhosis. (sages.org)
  • Bismuth, H., Franco, D., Hepp, J.: Portal-systemic shunt in hepatic cirrhosis: Does the type of shunt decisively influence the clinical result? (springer.com)
  • Portal hypertension is different from the high blood pressure (systemic hypertension) that many people develop as they get older. (northshore.org)
  • TIPSS stands for transjugular intrahepatic portal systemic shunt. (britishlivertrust.org.uk)
  • Indeed, the data from the 10mg dose cohort suggest that OCA may rapidly improve portal hypertension in patients without reducing systemic blood pressure. (cnbc.com)
  • Portal hypertension is characterized by increased cardiac output and decreased systemic vascular resistance, 7 which results in a hyperdynamic circulatory state with splanchnic and systemic arterial vasodilation. (cmaj.ca)
  • Angiogenesis has a pivotal role in the formation of portal-systemic shunts. (elsevier.es)
  • This suggests a central role of the liver in systemic and regional immune response, because KC come in contact with all the microbiological debris from the gastrointestinal tract reaching the liver via the portal vein. (bmj.com)
  • Embryologically, the systemic veins of our body develop from the intra-embryonic anterior and posterior cardinal veins while the portal system develops from the extra-embryonic vitelline and umbilical veins, which drain from the yolk sac and the placenta. (pediatriconcall.com)
  • Nakanuma Y, Sato Y, Kiktao A. Pathology and pathogenesis of portal venopathy in idiopathic portal hypertension: hints from systemic sclerosis. (springermedizin.de)
  • PPS percentage shunt index (%SI) (the amount of radionuclide that shunts the liver and reaches the systemic blood after injection in the rectum) was measured in 22 children (mean age, 7.2 ± 4.9 y) and compared with established clinical, laboratory, and endoscopic and imaging parameters of portal hypertension (PH). (snmjournals.org)
  • Per-rectal portal scintigraphy (PPS) with 99m Tc-pertechnetate is a technique that explores quite specifically the collateral flow that develops in PH from the portal system to the systemic circulation through the rectal venous bed ( 18 - 20 ). (snmjournals.org)
  • The gastrointestinal tract is the second cause of systemic compromise of this disease, but idiopathic portal hypertension is an extremely rare condition in these patients. (scielo.org.co)
  • We describe the case of a female patient with atypical hepatic changes of idiopathic portal hypertension associated with limited systemic sclerosis. (scielo.org.co)
  • Systemic sclerosis, portal hypertension, liver disease. (scielo.org.co)
  • The relevance of this case is the association of idiopathic portal hypertension with limited systemic sclerosis. (scielo.org.co)
  • At 14 days after the operation, systemic and portal haemodynamics were measured in stable or bleeding PVL rats receiving an intravenous infusion of glypressin (0.07 mg/kg). (clinsci.org)
  • Four patients with a long history of colitis, splenomegaly, hypersplenism and portal hypertension were examined with angiography, both with contrast medium and isotopes, liver-spleen scintigraphy and recording of portal pressure. (osti.gov)
  • misc{etde_6255215, title = {Splenomegaly, hyperkinetic splenic flow and portal hypertension in colitis} author = {Friman, L} abstractNote = {Four patients with a long history of colitis, splenomegaly, hypersplenism and portal hypertension were examined with angiography, both with contrast medium and isotopes, liver-spleen scintigraphy and recording of portal pressure. (osti.gov)
  • Portal hypertension and related splenomegaly and reserving of the platalets in the spleen is the most important reason for thrombocytopenia (21). (thefreedictionary.com)
  • Earlier described as Banti's disease, tropical splenomegaly syndrome or Bengal splenomegaly, or hepatoportal sclerosis, it is more popularly known as idiopathic portal hypertension (IPH), or non-cirrhotic portal fibrosis (NCPF) ( Figure 2 ). (clinicaladvisor.com)
  • In another model of indwelling cannulation of the gastrosplenic vein, repeated injections of Escherichia coli resulted in the development of splenomegaly and an increase in portal pressure at 3 months. (clinicaladvisor.com)
  • There are several reports of portal hypertension in children presenting with haematemesis and splenomegaly in whom the liver histology is normal and in whom the portal vein is patent. (pediatriconcall.com)
  • Purpose: To establish the importance of shunt surgery combined with partial resection of the spleen for selected pediatric patients with extra-hepatic portal vein obstruction (EHPVO), enormous splenomegaly and severe hypersplenism. (ebscohost.com)
  • The only evidence of portal hypertension may be splenomegaly in a patient with chronic liver disease. (brainscape.com)
  • A diagnosis of portal hypertension is unlikely if splenomegaly cannot be detected on USS. (brainscape.com)
  • As a matter of example, how to manage patients with clinical significant portal hypertension in whom, after etiological treatment, portal hypertension is just mild? (easl.eu)
  • Clinically significant portal hypertension is present when the gradient exceeds 10 mmHg and risk of variceal bleeding increases over 12 mmHg. (brainscape.com)
  • Determine the etiology of portal hypertension. (clinicaladvisor.com)
  • Epidemiology and etiology of Portal Hypertension. (easl.eu)
  • The field of portal hypertension (PHT) is currently challenged by variations in cirrhosis etiology ,and changes in the natural history of advanced chronic liver disease after controlling the etiological factor (i.e. (easl.eu)
  • Twelve patients with established alcoholic cirrhosis and portal hypertension were administered a 10mg daily dose of OCA for seven days. (cnbc.com)
  • While the researchers stress that a 'very careful approach' is needed in potential human trials of the drug, they encourage their colleagues to more closely examine the role of similar therapeutic agents that block blood vessel growth - called antiangiogenesis therapy - in patients with cirrhosis and portal hypertension. (psmag.com)
  • Long-term administration of GTPs inhibited the development of cirrhosis and portal hypertension by decreasing both hepatic resistance and splanchnic hyperdynamic circulation. (portlandpress.com)
  • The present study was to compare elective TIPS and laparoscopic splenectomy (LS) plus EVL in their efficacy in preventing recurrent bleeding and long-term improvement in liver function in patients with liver cirrhosis and portal hypertension. (sages.org)
  • Graziano, J.L., Sullivan, H.J.: Portal decompression: Clinical experience with the "H" graft. (springer.com)
  • In addition, the future directions of basic/clinical research in portal hypertension are discussed. (nih.gov)
  • Portal Hypertension is a topic covered in the 5-Minute Clinical Consult . (unboundmedicine.com)
  • 5minute , www.unboundmedicine.com/5minute/view/5-Minute-Clinical-Consult/116478/all/Portal_Hypertension. (unboundmedicine.com)
  • As there is a relative paucity in effective pharmacological treatment for portal hypertension, these novel and innovative therapy might provide important alternative or adjunct therapy to beta blockers in the clinical management of patients with portal hypertension. (clinicaltrials.gov)
  • NEW YORK, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced initial results from PESTO, an open-label Phase 2a trial evaluating the effects of obeticholic acid (OCA) for the treatment of portal hypertension. (cnbc.com)
  • See Table I for a listing of clinical features in portal hypertension, Table II for a listing of characteristic features, Table III less common clinical presentations, and Table IV for diseases and conditions that mimic the disease. (oncologynurseadvisor.com)
  • Portal hypertension is the abnormal pathophysiologic state that develops in liver cirrhosis and certain other disorders with characteristic clinical and hemodynamic features. (springer.com)
  • The clinical consequences of portal hypertension develop once portal pressure gradient increases to greater than 12 mmg Hg. (clinicaladvisor.com)
  • However, the likelihood of clinical problems increases as portal pressure rises. (clinicaladvisor.com)
  • GlobalData's clinical trial report, Portal Hypertension Global Clinical Trials Review, H1, 2013" provides data on the Portal Hypertension clinical trial scenario. (thefreedictionary.com)
  • In the present issue of Clinical Science , Hsu and co-workers show the beneficial effects of GTPs (green tea polyphenols) in improving portal hypertension. (portlandpress.com)
  • What are the clinical features of portal hypertension? (brainscape.com)
  • We evaluated the clinical usefulness of 99m Tc-pertechnetate per-rectal portal scintigraphy (PPS) in the assessment of portal circulation in children with chronic cholestasis. (snmjournals.org)
  • Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. (springermedizin.at)
  • Idiopathic portal hypertension associated with cytotoxic drugs. (bmj.com)
  • Four patients developed clinically important portal hypertension with histological features of idiopathic portal hypertension while they were receiving cytotoxic drugs for chronic myeloid leukaemia and Hodgkin's disease. (bmj.com)
  • There is an association between idiopathic portal hypertension and the use of chemotherapeutic agents, particularly thioguanine. (bmj.com)
  • Hidaka H, Ohbu M, Kokubu S, Shibuya A, Saigenji K, Okayasu I. Hepatocellular carcinoma associated with idiopathic portal hypertension: review of large nodules in seven non-cirrhotic portal hypertensive livers. (springermedizin.de)
  • Sato Y, Sawada S, Kozaka K, Harada K, Sasaki M, Matsui O, Nakanuma Y. Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. (springermedizin.de)
  • Kitao A, Sato Y, Sawada-Kitamura S, Harada K, Sasaki M, Morikawa H, Shiomi S, Honda M, Matsui O, Nakanuma Y. Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. (springermedizin.de)
  • Idiopathic portal hypertension is rare in patients with connective tissue disease (4). (scielo.org.co)
  • Offers both the option of diagnosing and treating etiologies for any secondary complications of portal hypertension. (oncologynurseadvisor.com)
  • Significant advances in the pathophysiology, diagnosis and management of the complications of portal hypertension that have occurred in the last year are reported. (ovid.com)
  • The specific areas reviewed are those that refer to experimental studies aimed at modifying the factors that lead to portal hypertension (increased intrahepatic vascular resistance and splanchnic vasodilatation) and recent advances in the diagnosis and management of the complications of portal hypertension. (ovid.com)
  • What are the possible complications of portal hypertension? (brighamandwomens.org)
  • The goal of this chapter is to provide an evidence-based approach to the endoscopic management of portal hypertension. (springer.com)
  • If you are at risk for or already have cirrhosis, your healthcare provider will likely do various lab tests, X-rays, and endoscopic exams to see if you have portal hypertension. (rochester.edu)
  • We will revise recent trials focused on the management of portal hypertension including pharmacological and endoscopic strategies but also innovative endovascular techniques such as TIPS, interventional thrombosis recanalization and BRTO. (easl.eu)
  • What are the signs and symptoms of portal hypertension? (drugs.com)
  • Mild cases of portal hypertension may not have any noticeable symptoms. (wisegeek.com)
  • The onset of portal hypertension may not always be associated with specific symptoms that identify what is happening in the liver. (clevelandclinic.org)
  • Having a higher than normal pressure inside the portal vein can lead to a number of related symptoms and complications. (rochester.edu)
  • It is medical condition called as silent killer as it does not show any clear symptoms however severe hypertension show some symptoms of headaches, sleepiness, palpitation, blurred vision, fatigue, dizziness, confusion, ringing sensation in the ears, breathing difficulty, irregular heartbeat which may lead to even coma. (4to40.com)
  • Portal hypertension may be clinically silent or it may present with life-threatening gastrointestinal symptoms, such as bleeding. (oncologynurseadvisor.com)
  • Signs and symptoms are varied and related to the underlying cause of the portal hypertension. (oncologynurseadvisor.com)
  • When it becomes severe enough to cause symptoms or complications, treatment may be given to decrease portal hypertension itself or to manage its complications. (wikipedia.org)
  • Portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. (nih.gov)
  • Play media Hypertension is rarely accompanied by symptoms, and its identification is usually through screening, or when seeking healthcare for an unrelated problem. (wikipedia.org)
  • Hypertension with certain specific additional signs and symptoms may suggest secondary hypertension, i.e. hypertension due to an identifiable cause. (wikipedia.org)
  • other, less frequent causes are therefore grouped as non-cirrhotic portal hypertension. (wikipedia.org)
  • The diagnosis may not be so obvious in children with non-cirrhotic portal hypertension. (pediatriconcall.com)
  • Herein, we discuss isolated liver TB and the differential diagnosis of non-cirrhotic portal hypertension. (ajtmh.org)
  • In endemic areas, TB should be considered in the differential diagnosis of non-cirrhotic portal hypertension. (ajtmh.org)
  • Non-cirrhotic portal hypertension-diagnosis and management. (springermedizin.de)
  • Histological features in western patients with idiopathic non-cirrhotic portal hypertension. (springermedizin.de)
  • Path physiology of cirrhotic portal hypertension. (medigraphic.com)
  • Based on the number of well-documented cases received by the FDA and exclusion of other causes of portal hypertension such as alcohol-related cirrhosis or hepatitis C, the FDA concludes there is an association between use of didanosine and the development of non-cirrhotic portal hypertension. (empr.com)
  • Stomach showed changes of portal gastropathy. (pediatriconcall.com)
  • Gastric mucosal changes such as presence of mosaic pattern, cherry red spots and scarlatina rash on endoscopy are called as portal hypertensive gastropathy which are also not uncommon. (pediatriconcall.com)
  • Short-term effects of variceal sclerotherapy on portal hypertensive gastropathy. (medigraphic.com)
  • The natural history of portal hypertensive gastropathy: influence of varicel eradication. (medigraphic.com)
  • Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. (acpjc.org)
  • To assess the effectiveness of propranolol in preventing recurrence of bleeding from severe portal hypertensive gastropathy in patients with liver cirrhosis. (acpjc.org)
  • 38 patients with hepatoma, contraindications to propranolol previous β-blocker therapy, massive portal hypertensive gastropathy hemorrhage, or who refused consent, were excluded. (acpjc.org)
  • Propranolol, at an average dose of 120 mg/d, decreased the incidence of recurrent bleeding from severe portal hypertensive gastropathy in patients with liver cirrhosis. (acpjc.org)
  • The gastric lesion, now called portal hypertensive gastropathy, results from longstanding portal hypertension. (acpjc.org)
  • Progression of portal hypertension results in splanchnic vasodilation and angiogenesis. (unboundmedicine.com)
  • Chronic peripheral and splanchnic vasodilatation are the hallmark hemodynamic abnormality in cirrhosis and contribute to the pathogenesis of portal hypertension. (clinicaltrials.gov)
  • Portal hypertension results from increased intrahepatic vascular resistance and portal-splanchnic blood flow. (cmaj.ca)
  • Splanchnic arterial vasodilation leads to increased portal blood flow and thus elevated portal hypertension. (cmaj.ca)
  • Splanchnic arterial vasodilation leads to increased portal blood flow, which in turn leads to more severe portal hypertension. (cmaj.ca)
  • Portal vein is formed by the confluence of splenic vein and the superior mesenteric vein that carry blood from the splanchnic circulation to the liver. (clinicaladvisor.com)
  • For example, inhibition of VEGF reduces portal pressure, hyperdynamic splanchnic circulation, portosystemic collateralization and liver fibrosis. (elsevier.es)
  • Consequences of portal hypertension include development of ascitic effusion, splanchnic vasodilation, risk of bleeding from APSSs, development of a portal-enteric vascuolopathy, and increased risk of septic abdominal effusion. (merckvetmanual.com)
  • The standard treatment to reduce splanchnic portal hypertension in people is nonselective β-blockade using propranolol , administered to control or reduce risk of spontaneous bleeding from APSSs. (merckvetmanual.com)
  • Haemorrhage is associated with the endogenous release of bradykinin, which may subsequently stimulate the formation of nitric oxide (NO). The present study investigated the relative contribution of NO synthase (NOS) isoforms and the role of bradykinin in the pathogenesis of splanchnic hyposensitivity to a long-acting vasopressin analogue, glypressin, in rats with portal hypertension induced by partial portal vein ligation (PVL). (clinsci.org)
  • It is concluded that constitutive NOS and bradykinin are responsible, at least partly, for the splanchnic hyposensitivity to glypressin observed in the early stages of the haemorrhage/transfused rat model of portal hypertension. (clinsci.org)
  • TY - JOUR T1 - Pathophysiology of portal hypertension and variceal bleeding. (unboundmedicine.com)
  • The pressure in the portal vein may rise because there is a blockage, such as a blood clot, or because the resistance in the liver is increased because of scarring (fibrosis) or cirrhosis . (britishlivertrust.org.uk)
  • Noncirrhotic portal fibrosis (NCPF) and extrahepatic portal vein obstruction (EHPVO) are two diseases that are common in developing countries and most often present only with features of portal hypertension and not of parenchymal dysfunction ( Figure 1 ). (clinicaladvisor.com)
  • ABSTRACT- To clarify the relation of pericentral fibrosis to portal hypertension, measurements of portal vascular resistance in vitro and blood pressures of several key points in hepatic vascular pathways in vivo were undertaken in rats given dimethylnitrosamine. (wiley.com)
  • These data suggest that deformation of the peripheral branches of the hepatic vein due to pericentral fibrosis causes a marked increase in vascular resistance in the intrahepatic hepatic vein, i.e. postsinusoidal portal hypertension. (wiley.com)
  • Non-cirrhotic portal fibrosis: one disease with many names? (springermedizin.de)
  • Can primary biliary cholangitis (PBC) cause portal hypertension? (webmd.com)
  • What are the dynamic factors that account cause portal hypertension in cirrhosis? (medscape.com)
  • Although TB has been known to cause portal hypertension in a variety of ways, this case was notable for the presence of periportal inflammation and granulomas, also seen in hepatic schistosomiasis. (ajtmh.org)
  • Portal hypertension is high blood pressure in the veins that filter blood from the intestines through the liver (portal system of the liver). (northshore.org)
  • Portal hypertension is high blood pressure in the portal vein and associated veins that flow into it. (patientslikeme.com)
  • The portal vein is responsible for guiding blood from the stomach and intestines, where it then breaks into smaller veins. (wisegeek.com)
  • Other possible causes of portal hypertension are hepatitis C and thrombosis , or blood clots of the portal veins. (wisegeek.com)
  • More severe cases of portal hypertension can be treated with surgery to physically reroute the veins leading to the liver. (wisegeek.com)
  • A common surgical treatment procedure is a transjugular intrahepatic portosystemic shunt (TIPS), an operation in which a surgeon attaches the portal vein onto the veins of the liver known as hepatic veins. (wisegeek.com)
  • These smaller and newly formed veins may be much weaker than the portal vein and may swell up and burst under the added pressure. (rochester.edu)
  • The small veins overloaded because of portal hypertension can burst and cause internal bleeding. (rochester.edu)
  • He or she then connects the shunt to one of the hepatic veins, creating another pathway which blood can flow through and reducing pressure in your portal vein as well as other abdominal veins. (nyp.org)
  • CHF is an inherited disease that affects both liver and kidneys and it could cause scarring and hardening of the liver, which makes it more difficult for the blood to flow through it thus causing a condition called portal hypertension , where there is increased pressure in the veins that carry blood to the liver. (thefreedictionary.com)
  • It is conceivable that an acute and transient disease of the portal vein, or the liver, or the hepatic veins may determine an acute and transient increase of portal vein pressure. (springer.com)
  • Increased endogenous vasodilators in turn promote more blood flow in the portal veins. (wikipedia.org)
  • Able to characterize the velocity and directionality of flow of blood within the portal vein while analyzing the hepatic veins and hepatic arteries simultaneously. (oncologynurseadvisor.com)
  • However, the facilitory effect of yohimbine was significantly attenuated in portal veins obtained from SHR at 28 weeks of age compared to age-matched WKY. (ahajournals.org)
  • This is a presentation of a unique case of pulmonary hypertension in a 15-year-old girl, due to micro-thromboembolism from splenoportal veins through a portacaval anastomosis. (bmj.com)
  • What veins form the hepatic portal vein? (brainscape.com)
  • Blood vessels enter the liver via the hilum (porta hepatis) and blood passes into the hepatic sinusoids via the portal tracts and leaves the liver through the hepatic veins to join the IVC. (brainscape.com)
  • The increased pressure in the portal vein also causes pressure to increase in other veins. (childrenscolorado.org)
  • It is often defined as a portal pressure gradient (the difference in pressure between the portal vein and the hepatic veins) of 5 mm Hg or greater. (thefullwiki.org)
  • It results from a combination of increased intrahepatic vascular resistance and increased blood flow through the portal venous system. (cmaj.ca)
  • According to Ohm's law, portal venous pressure (P) is the product of vascular resistance (R) and blood flow (Q) in the portal bed (P = Q × R). Intrahepatic resistance increases in 2 ways: mechanical and dynamic. (cmaj.ca)
  • 2 The dynamic component results from a vasoconstriction in portal venules secondary to active contraction of portal and septal myofibroblasts, to activated hepatic stellates cells and to vascular smooth-muscle cells. (cmaj.ca)
  • Portal hypertension generally results from increased vascular resistance. (clinicaladvisor.com)
  • A hipertensão portal é uma complicação secundária à cirrose que tem como característica aumento do fluxo sanguíneo e/ou resistência vascular no sistema porta, causando o surgimento de uma circulação colateral hiperdinâmica. (scielo.br)
  • The portal vascular resistance was increased and the portal vein pressure was elevated markedly. (wiley.com)
  • Histopathological evaluation of the polyp showed numerous thick-walled capillaries in its subepithelial portion, and a few vascular ectasias suggestive of portal hypertensive duodenopathy. (pediatriconcall.com)
  • Portal hypertension may also be caused by thrombosis , or a blood clot that develops in the portal vein. (clevelandclinic.org)
  • Abdominal infection and diarrheal episodes at birth or in early childhood are likely to lead to portal pyemia and pylephlebitis, which could result in thrombosis, sclerosis, and obstruction of small- and medium-sized portal vein radicals. (clinicaladvisor.com)
  • However, at times, a history of umbilical vein cannulation, abdominal infection, trauma or pancreatitis may be responsible for the portal thrombosis. (pediatriconcall.com)
  • In presinusoidal portal hypertension, there is obstruction or stenosis in the portal vein, its tributaries, or intrahepatic branches. (oncologynurseadvisor.com)
  • Variceal bleeding is associated with a mortality rate of 5 - 9 percent in children with portal vein obstruction but there is a higher risk of death of those with cirrhosis. (pediatriconcall.com)
  • Further studies have shown a subendothelial thickening of intrahepatic branches of the portal vein causing presinusoidal obstruction to portal blood flow within the liver leading to the formation of collateral venous channels in the porta hepatis. (pediatriconcall.com)
  • What are the main sites of obstruction of the portal vein leading to portal hypertension? (brainscape.com)
  • The inflow of portal blood to the liver can be partially or completely blocked at a number of sites, leading to high pressure proximal to the site of obstruction and the diversion of blood into portosystemic anastamoses. (brainscape.com)
  • The drug was well tolerated in all twelve patients and, of the eight patients assessed for changes in portal pressure, five met the primary efficacy endpoint with a clinically significant improvement in hepatic venous pressure gradient (HVPG), the standard measurement of portal pressure in such patients. (cnbc.com)
  • Compensatory imbalance of sodium and water homeostasis becomes clinically apparent at the onset of portal hypertension and is typically associated with a subnormal albumin concentration. (merckvetmanual.com)
  • The other patient was operated on with a diagnosis of extrahepatic presinusoidal portal hypertension caused by extrinsic compression of the liver by an hydatid cyst. (hindawi.com)
  • Intrahepatic causes of portal hypertension are categorized as presinusoidal, sinusoidal, and postsinusoidal. (merckvetmanual.com)
  • Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. (springer.com)
  • Medications to decrease portal pressure and gastrointestinal blood flow, and antibiotics. (columbiasurgery.org)
  • We included 17 patients with portal hypertension treated with terlipressin (Group 1), 7 with portal hypertension treated with somatostatin/octreotide (Group 2), 20 with acute non-variceal gastrointestinal bleeding treated with somatostatin/octreotide (Group 3), and 19 with acute pancreatitis treated with somatostatin/octreotide (Group 4). (intechopen.com)
  • The degree of portal hypertension at the time of the procedure is correlated with a shorter time to requiring liver transplantation, reflecting liver pathophysiology in a more functional way. (thefreedictionary.com)
  • In developing therapeutic alternatives to liver transplantation, we have used the strategy of applying a small intestinal segment as a scafold for hepatocyte transplantation and also as a portocaval shunt (pcs) system to address both liver dysfunction and portal hypertension. (ebscohost.com)
  • Yes Nadolol is the appropriate treatment for portal hypertension. (medhelp.org)
  • Impact of portal hemodynamics on Doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis. (medscape.com)
  • Hyposensitivity to vasopressin is a well documented phenomenon in animals with portal hypertension and patients with cirrhosis subject to haemorrhage. (clinsci.org)
  • Prehepatic causes include stenosis, stricture, or thrombi involving the extrahepatic portal vein. (merckvetmanual.com)
  • A 7 years old boy suffering from extrahepatic portal hypertension had an episode of malena. (pediatriconcall.com)
  • In patients with moderate to severe portopulmonary hypertension, beta-blockers are associated with significant worsening in exercise capacity and pulmonary hemodynamics. (greenmedinfo.com)
  • Ultrasonic diagnosis of portal hypertension. (bmj.com)
  • Various modalities in the diagnosis of portal hypertension are reviewed. (koreamed.org)
  • The diagnosis of portal hypertension should be suspected in a child after the occurrence of any large gastro-intestinal bleed. (pediatriconcall.com)
  • Many of these patients have the stigmata of their underlying disease and the diagnosis of portal hypertension is not difficult. (pediatriconcall.com)
  • In people with portal hypertension, there is increased pressure in the portal vein-the major vein transporting blood through your liver. (nyp.org)
  • At NewYork-Presbyterian, our liver disease specialists have the skills and expertise to care for people with portal hypertension and are leaders in the development of innovative treatments for this disease. (nyp.org)
  • Boyer, T. D. and Haskal, Z. J. (2005), The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. (wiley.com)
  • Zuo C, Chumbalkar V, Ells PF, Bonville DJ, Lee H. Prevalence of histological features of idiopathic noncirrhotic portal hypertension in general population: a retrospective study of incidental liver biopsies. (springermedizin.de)
  • In more severe situations, your healthcare provider may treat portal hypertension with shunting. (rochester.edu)
  • Portal hypertension is a dangerous condition with severe, life-threatening complications. (rochester.edu)
  • It is easy to get prevented from the primary hypertension however secondary hypertension is severe condition which can be managed and cured if treated well. (4to40.com)
  • The study of 100 patients with hepatitis C and compensated cirrhosis showed that the probability of developing a first episode of liver decompensation at 1, 5, and 7 years was 4%, 25%, and 28%, respectively, among patients with an hepatic venous pressure gradient (HVPG) value of 10 mm Hg or above, compared with 0, 0, and 16% in patients without cirrhosis with severe portal hypertension (CSPH). (thefreedictionary.com)
  • Portal hypertension also commonly occurs in children with severe liver disease. (childrenscolorado.org)
  • Portal hypertension is defined as an increase in blood pressure in the portal venous system. (cmaj.ca)
  • An increase in the portocaval pressure gradient leads to the formation of portosystemic venous collaterals in an attempt to decompress the portal venous system. (cmaj.ca)
  • A rise in pressure in the portal venous system is termed portal hypertension. (clinicaladvisor.com)
  • The portal venous system is the only venous system in our body, which begins with capillaries and ends with capillaries. (pediatriconcall.com)
  • To our knowledge, only one case of sarcoidosis with combined portal and pulmonary hypertension has previously been described. (nih.gov)
  • Echocardiography showed pulmonary hypertension (PAP: 47 mmHg). (scielo.org.co)
  • Portal hypertension is high blood pressure in the portal vein of your liver. (drugs.com)
  • Unfortunately, healthcare providers can't measure high blood pressure in the portal vein with a cuff as they can regular high blood pressure. (rochester.edu)
  • This is an increase in the blood pressure in the portal vein, which carries the blood from the bowel and spleen to the liver. (britishlivertrust.org.uk)
  • As a result, the pressure in the portal vein rises. (britishlivertrust.org.uk)
  • Portal hypertension is abnormally high blood pressure in the portal vein, which supplies the liver with blood from the intestine. (stlouischildrens.org)
  • Portal hypertension results from increased pressure in the portal vein, which feeds most of the blood supply to the liver. (cnbc.com)
  • Portal hypertension is elevated blood pressure in the portal vein, the major vein that carries blood to the liver. (columbiasurgery.org)
  • Portal hypertension is abnormally increased portal venous pressure - blood pressure in the portal vein and its branches, that drain from most of the intestine to the liver. (wikipedia.org)
  • This raises the pressure in the portal vein. (brighamandwomens.org)
  • Recovery rates were poor, particularly in patients with portal hypertension ( high blood pressure in the portal vein that carries blood from the gut to the liver), and the side-effects were huge. (medicalxpress.com)
  • In medicine , portal hypertension is hypertension (high blood pressure) in the portal vein and its tributaries. (thefullwiki.org)
  • Noradrenergic transmission in the isolated portal vein of the spontaneously hypertensive rat. (ahajournals.org)
  • The effect of electrical field stimulation (1, 2, 5, 10 Hz for a total of 480 pulses at 15-minute intervals) on the release of 3H-norepinephrine from the superfused portal vein of spontaneously hypertensive rats (SHR) or Wistar-Kyoto rats (WKY) of various ages was studied. (ahajournals.org)
  • Histomorphometric study of portal hypertensive enteropathy. (pediatriconcall.com)
  • One consequence of chronic liver disease can be portal hypertension. (britishlivertrust.org.uk)
  • The further course was characterized by progressive chronic intrahepatic cholestasis and portal hypertension. (nih.gov)
  • The former is most likely if they have stigmata of chronic liver disease and portal hypertension and the latter assumed in the absence of these findings. (thefreedictionary.com)
  • The actuality of this research is caused by significant growth of the incidence of portal hypertension in patients with diffuse chronic liver disease in recent years [1-5]. (thefreedictionary.com)
  • Further research is warranted to determine whether there are benefits of portal use for other chronic conditions. (jabfm.org)
  • 4 A recent systematic review of the impact of patient portals on chronic disease management concluded that the evidence is insufficient to draw conclusions regarding their benefit. (jabfm.org)
  • The aim of PESTO is to assess the ability of OCA to similarly reduce portal hypertension in patients acutely, after only a week of treatment, via a mechanism independent of any longer term anti-fibrotic effects. (cnbc.com)
  • FLAGSTAFF, Ariz. - August 1, 2017 - The GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion, a new device configuration developed by W. L. Gore & Associates, Inc. (Gore), may further reduce portal hypertension treatment complications, even compared to the GORE® VIATORR® TIPS Endoprosthesis , Gore's legacy TIPS device, which has a strong history of patency and proven performance at fixed diameters. (goremedical.com)
  • PESTO is designed to evaluate OCA's ability to reduce hepatic portal venous pressure in patients with liver cirrhosis, first testing a 10mg dose and then proceeding with a 25mg dose (still ongoing). (cnbc.com)
  • Partial portal vein ligation is an experimental model used in rats to study the pathophysiological mechanisms involved in pre-hepatic portal hypertension. (scielo.br)
  • In all cases of hepatic portal hypertension, intrahepatic portal hypoperfusion (portal perfusion pressure is ~5-8 mmHg) is compensated by an increase in hepatic arterial perfusion that maintains organ circulation. (merckvetmanual.com)
  • Normally, blood from the spleen and intestines is filtered through the liver by way of the portal vein. (northshore.org)
  • The portal vein is formed by the union of the superior mesenteric (from the gut) and the splenic vein (from the spleen) and carries blood to the liver. (brainscape.com)
  • Portal hypertension is an increase in the blood pressure within the portal vein, a blood vessel that carries blood from the stomach, intestine, spleen and pancreas to the liver. (childrenscolorado.org)
  • Sinusoidal portal hypertension, the most common type of portal hypertension, is usually the result of cirrhosis. (oncologynurseadvisor.com)
  • various pathologic processes are thought to contribute to increased intrahepatic resistance at the level of the hepatic microcirculation (sinusoidal portal hypertension): architectural distortion of the liver due to fibrous tissue, 1 regenerative nodules, 1 and collagen deposition in the space of Disse. (cmaj.ca)
  • Intrahepatic portal hypertension is classified as pre-sinusoidal (schistosomiasis, early primary biliary cirrhosis), sinusoidal (alcoholic cirrhosis) and post-sinusoidal (alcoholic hepatitis, veno-occlusive disease). (clinicaladvisor.com)
  • The arterio-portal fistula (APF) is a rare, treatable and reversible cause of pre-sinusoidal portal hypertension (PPH). (elsevier.es)
  • Your team uses comprehensive diagnostic testing to diagnose portal hypertension, including endoscopy, ultrasound, MRI and other imaging tests. (nyp.org)